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RESUMO 
Os tumores genito-urinários incluindo os cancros da bexiga, rim e próstata estão 
entre as dez neoplasias malignas mais incidentes em todo o mundo. A elevada morbilidade 
e mortalidade associada a estas doenças, bem como a falta de ferramentas eficientes de 
deteção precoce, torna-os importantes alvos de investigação. O carcinoma de células 
renais (CCR) é o tumor urológico com a taxa de mortalidade mais elevada. Embora a 
maioria dos doentes com CCR apresentem doença localizada no momento do diagnóstico, 
uma percentagem destes doentes irá progressivamente metastizar. Além disso, cerca de 
um terço dos doentes com CCR são diagnosticados já com doença avançada. Embora, os 
inibidores das TKs (tyrosine kinases) apresentem uma melhor taxa de sobrevivência aos 5 
anos, esta não ultrapassa os 10%, não existindo ainda terapias com fins curativos para 
estes estádios. 
Atualmente, é geralmente aceite que as alterações ao nível da maquinaria 
epigenética, especialmente a hipermetilação de genes supressores tumorais, contribui 
para o desenvolvimento e progressão do cancro. É de realçar que ao contrário das 
modificações genéticas, as alterações epigenéticas são reversíveis, podendo os inibidores 
das DNMTs (DNA methyltransferases) constituir uma ferramenta terapêutica útil para 
doentes com CCR metastático. 
Neste estudo foi inicialmente avaliada a utilidade de quatro novos compostos, 
derivados das flavanonas, como agentes antineoplásicos em linhas celulares dos três 
tumores urológicos mais incidentes (da bexiga, rim e próstata), bem como o seu papel na 
inibição das DNMTs. Neste sentido, o perfil global da metilação do DNA de linhas celulares 
de tumores urológicos foi igualmente avaliado. As linhas celulares T24, ACHN e LNCaP 
apresentaram os maiores níveis de 5-metilcitosina. Após calcular o valor de IC50 para cada 
composto, o MLo-1302 obteve o valor de IC50 médio mais baixo (1.5 µM) e foi escolhido 
para o ensaio de viabilidade nas linhas celulares referidas. Uma vez que a ACHN mostrou 
ser a linha celular mais sensível, o cancro do rim foi o modelo tumoral escolhido para validar 
o papel destes compostos.  
Deste modo, o objetivo principal desta dissertação foi avaliar a atividade 
desmetilante e anti-tumoral de quatro novos compostos derivados das flavanonas em 
linhas celulares de CCR. Curiosamente, todos os compostos induziram inibição da 
viabilidade celular dependente da dose e do tempo, bem como um aumento significativo 
da apoptose em todas as linhas celulares testadas, tendo os compostos DD880 e MLo-
1302 mostrado ser os mais eficazes. A diminuição da expressão de KI67 acompanhada do 
aumento da expressão dos genes CDKN1A e CASP3 permitiu corroborar os dados 
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fenotípicos. Adicionalmente, e de uma forma geral, todos os compostos induziram 
alterações morfológicas e dano no DNA nas linhas celulares de CCR. A indução de dano 
genómico pode ser de elevada importância uma vez que a reparação do DNA é 
considerada um mecanismo de resistência à terapia. Considerando o potencial 
desmetilante dos compostos, o maior efeito inibitório na expressão das DNMTs, reduzindo 
a DNMT1 na Caki-2 e a DNMT3a em todas as linhas avaliadas foi obtido com o MLo-1302. 
Além disso, este composto também diminuiu significativamente a atividade da DNMT3A na 
linha celular Caki-2. Embora os outros três compostos também tenham induzido efeitos ao 
nível da expressão das DNMTs, esse efeito não foi tão pronunciado e consistente como na 
exposição ao composto MLo-1302. A expressão do gene TET1 (Ten-eleven translocation) 
aumentou após exposição aos compostos DD880 e MLo-1302 em quase todas as linhas 
celulares. Para além disso, estes mesmos agentes induziram a expressão dos genes TET2 
e TET3 em algumas linhas. Globalmente, o composto MLo-1302 induziu uma redução 
acentuada no conteúdo de 5-metilcitosina em todas as linhas celulares testadas. O 
composto MLo-1302 reduziu, igualmente, a metilação do promotor do gene RASSF1A com 
concomitante re-expressão na linha ACHN.  
Em conclusão, demonstramos pela primeira vez que novos compostos sintetizados 
derivados das flavanonas atenuam o fenótipo maligno das células de CCR. De uma forma 
geral, o composto MLo-1302 mostrou ser o mais eficaz quer a nível fenotípico, quer ao 
nível molecular. Deste modo, constitui um composto promissor para a terapia do CCR 
avançado, embora estudos adicionais sejam ainda necessários para melhor caracterização 
da eficácia e perfil de toxicidade em ensaios in vitro e in vivo.  
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ABSTRACT 
Genitourinary tumors, comprising bladder, kidney and prostate cancers, are among 
the ten most incident malignancies worldwide. The high morbidity and mortality associated 
with these diseases as well as the lack of efficient early detection tools render them as an 
important field to be investigated. Interestingly, Renal Cell Carcinoma (RCC) is the 
urological tumor with highest mortality rate. Although most RCC patients present with 
localized disease at diagnosis, a significant proportion eventually progresses through 
metastization, whereas about one third are diagnosed with advanced and poor prognosis 
disease. At this stage, there are no available curative therapies and targeted therapy with 
tyrosine kinase inhibitors (TKIs) endows 5-year survival rate lower than 10%. 
Currently, it is widely accepted that aberrations in epigenetic machinery, especially 
hypermethylation of tumor suppressor genes (TSGs), contribute to RCC development and 
progression. Importantly, unlike genetic alterations, epigenetic aberrations are reversible, 
and thus DNA methyltransferase inhibitors (DNMTi) might be a useful therapeutic tool for 
RCC patients with metastatic disease. 
In a preliminary approach, the anti-neoplastic and DNMTs inhibition activity of four 
newly synthetized flavanones-derived compounds was tested in cell lines of the three most 
incident urological tumors (bladder, kidney and prostate cancers). In parallel, global DNA 
methylation profile of urological tumors cell lines was also assessed. T24, ACHN and 
LNCaP were those from each tumor model that displayed the highest levels of 5-
metylcytosine. Following IC50 value calculation for each compound, MLo-1302 
demonstrated the lowest IC50 mean value (1.5 µM) and was chosen to perform the viability 
assay in the previously selected cell lines. Since ACHN cells were the most sensitive, kidney 
cancer was the selected tumor model to validate the role of these flavanone-derived 
compounds.  
Thus, considering the preliminary data, the major objective of this master 
dissertation was to evaluate the demethylating and anti-tumoral activity of the four new 
flavanones-derived compounds in RCC cell lines. Interestingly, all compounds induced a 
time- and dose-dependent inhibition of cell viability, as well as a significant increase in 
apoptosis in all tested cell lines, with DD880 and MLo-1302 being the most effective 
compounds. Decrease in KI67 expression along with increased CDKN1A and CASP3 
expression levels corroborated the phenotypic data. Moreover, in general, all four 
compounds induced morphological alterations and DNA damage in all cell lines. The 
induction of DNA damage might be extremely important since DNA repair is considered a 
mechanism of tumor resistance to therapy. Concerning their demethylation potential, MLo-
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1302 induced the higher inhibitory effect on DNMTs expression, reducing DNMT1 in Caki-
2 and DNMT3a in all tested cell lines. Additionally, this compound also significantly 
decreased DNMT3A activity in Caki-2 cell line. Although the other three compounds also 
affected DNMTs expression, it was less impressive and consistent than MLo-1302. 
Furthermore, DD880 and MLo-1302 significantly incremented TET1 transcript levels in 
almost all treated cell lines. Likewise, TET2 and TET3 expression was also increased in 
some cell lines treated with these agents. Globally, MLo-1302 induced a significant 5-
methylcytosine content reduction in all RCC cell lines, particularly in ACHN. The MLo-1302 
demethylating effect reduced loci-specific promoter methylation of RASSF1A with 
concomitant gene re-expression in ACHN cell line.  
We demonstrated for the first time that new synthetized flavanones-derived 
compounds attenuate RCC cells malignant phenotype. Globally, MLo-1302 was the most 
effective compound both at phenotypic and molecular levels. Thus, it constitutes a 
promising compound for treatment of advanced renal cancer, requiring further testing to 
determine its efficacy and toxicity in vitro and in vivo assays. 
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Urological Tumors 
Urological tumors, comprising bladder, kidney, prostate and testicular tumors, are 
an heterogeneous class of malignancies associated with significant morbidity and mortality 
rates worldwide [1]. The first entities are among the 10 most frequent cancers in men, being 
testicular germ cell tumors (TGCTs) the less frequent. However, TGCTs represent the most 
common cancers in young men [2]. For 2012, it was estimated 14.1 million new diagnosed 
cases and 8.2 million cancer deaths from all urological cancers worldwide. Importantly, the 
majority of these tumors are asymptomatic at early disease stage and there are only few 
blood biomarkers for disease detection [3, 4]. Due to their higher incidence and mortality 
rates, it is imperative to improve not only early detection approaches but also new and more 
effective therapeutic strategies.  
 
Epigenetics Concept 
Epigenetics is defined as the study of heritable modifications of DNA or associated 
proteins that carries information related to gene expression during cell division. Unlike 
genetic abnormalities, epigenetic changes do not alter the DNA sequence and are 
potentially reversible [5]. In mammals, epigenetic inheritance is important for pre-
implantation and fetal development, as well as, cell and tissue differentiation [6-9]. 
Epigenetic regulation comprises four major mechanisms: DNA methylation, histone post-
translation modifications or chromatin remodeling, histone variants and non-coding RNAs’ 
regulation. Thus far, DNA methylation is the best studied epigenetic mechanism [10]. All 
cancer types, harbor several epigenetic aberrations that directly contribute to malignant 
transformation and tumor progression [11]. Due to the reversibility of these alterations, 
modulation of the epigenetic machinery might provide new attractive therapeutic 
approaches in cancer [12].  
The introduction of this dissertation summarizes the recent advances of epigenetic 
therapy, namely DNA methylation inhibitors (DNMTi), in the treatment of urological tumors.     
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DNA Methylation 
DNA methylation consists in a covalent addition of a methyl group to the 5’ carbon 
of a cytosine ring, mainly within a CpG dinucleotide, resulting on the formation of a new 
DNA base, 5-methylcytosine (5mC). This process is catalyzed by DNA methyltransferases 
(DNMTs) being S-adenosyl-L-methionine (SAM) the donor of the methyl group (Figure 1) 
[13, 14].   
Figure 1 - DNA methylation reaction catalyzed by DNMTs using SAM as a methyl group donor.  
There are three well known DNMTs enzymes that catalyze DNA methylation: 
DNMT1, DNMT3A and DNMT3B. DNMT1 is mainly responsible for the maintenance of 
parental cell DNA methylation within the newly synthesized DNA strand during cell division 
[15-17], while DNMT3A and DNMT3B have both de novo methylation activity [18, 19]. 
Importantly, the addition of the methyl group to cytosine does not interfere with the Watson-
Crick base paring of the nucleotide. This group is inserted in the major groove of DNA, 
where it can be efficiently recognized by DNA-interacting proteins [20]. DNA methylation is 
closely linked to control of gene expression either by inhibiting the binding of transcription 
factors through direct methylation of CpGs dinucleotides within their binding sites and/or by 
acting as binding sites for methyl-CpG binding protein domains (MBDs). MBDs associated 
with other factors such as histones deacetylases (HDACs) can establish repressive 
chromatin structures (Figure 2) [21-23].  
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Figure 2 - Transcription regulation by DNA methylation. RNA pol: RNA polymerase; DNMTs: DNA 
methyltransferases; HDACs: Histone Deacetylases; MBDs: Methylcytosine-binding protein domain. 
 
Methylation patterns are clonally inherited and preserved in daughter cells through 
replicative DNA methylation by DNMTs enzymes [24]. DNA methylation can be reverted 
through an active or a passive mechanism, or by a combination of both [25, 26]. Both 
maternal and paternal genome are active and passive demethylated just before the first 
mitotic division following fertilization [26-29]. Active demethylation comprises oxidation 
mediated by TET (ten-eleven translocation) proteins, and entrance into BER (Base Excision 
Repair) pathway [25]. TET family includes TET1, TET2 and TET3 proteins identified as 
dioxygenases which catalyzes the oxidation of 5mC to 5-hydroxymethylcytosine (5hmC) 
[30, 31]. On the other hand, passive demethylation consists in gradual methylation loss 
through lack of maintenance during DNA replication, such as predominant exclusion of 
DNMT1 from the nucleus [32]. Changes in DNA methylation pattern have been described 
in several human diseases, including cancer [21]. In fact, in cancer cells, gain in DNA 
methylation at gene promoters (hypermethylation), that are normally unmethylated, leads 
to gene inactivation (Figure 3A). Concomitantly, demethylation of normally methylated 
regions have been associated with chromosomal instability and activation of proto-
oncogenes (hypomethylation) (Figure 3B) [11, 33]. Although, the mechanisms underlying 
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these aberrant DNA methylation patterns are largely unknown, several studies 
demonstrated that they arise early in tumor development [34, 35].  
 
Figure 3 - DNA methylation patterns and chromatin conformation in normal and cancer cells in (A) CpG island 
(CGIs) in promoter region of TSGs and (B) repetitive sequences.  
DNMTs inhibitors 
During the last decades several compounds were described as being able to restore 
the normal methylation patterns by irreversibly inhibiting the DNMTs enzymatic activity and 
triggering their proteasomal degradation [36, 37]. This in turn, actively contributes to tumor 
cell reversion phenotype which might translate into significant clinical benefits for patients 
[38]. Indeed, two epigenetic compounds that target DNA methylation and four HDAC 
inhibitors were already approved by Food and Drug Administration (FDA) for cancer 
treatment (Table 1) [39-41].  
 
  
A B 
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Table 1 – US FDA-approved drugs that target the epigenome. 
Drug Class Target Date Cancer type Pharmaceutical 
Company 
5-Azacytidine 
Azacytidine (Vidaza) 
DNMTi DNMT proteins  2004 Myelodysplastic 
syndrome (MDS) 
Celgene Corporation 
(and generic) 
5-Aza-2’-deoxycytidine 
Decitabine (Dacogen) 
DNMTi DNMT proteins 2006 Acute Myeloid 
Leukemia (AML) 
and MDS 
Otsuka 
Pharmaceutical  
(and generic) 
SAHA  
Vorinostat (Zolinza) 
HDACi HDAC class I, II 
and IV proteins 
2006 Cutaneous T cell 
lymphoma 
Merck & Co. 
FK-228 
Romidepsin (Istodax) 
HDACi HDAC class I 
proteins 
2010 Cutaneous T cell 
lymphoma 
Celgene 
PXD101 
Belinostat (Beleodaq) 
HDACi HDAC class I and 
II proteins 
2014 Peripheral T cell 
lymphoma 
Spectrum 
Pharmaceuticals 
LBH-589 
Panobinostat (Farydak) 
HDACi HDAC class I, II 
and IV proteins 
2015 Multiple myeloma Novartis 
SAHA: suberoylanilide hydroxamic acid. 
DNMTi can be divided in two classes depending on their mode of action, namely 
nucleoside and non-nucleoside analogues (Figure 4) [42]. 
 
Figure 4 - Mechanism of action of nucleoside and non-nucleoside analogues DNMT inhibitors. 
 
 Nucleoside analogues  
Nucleoside analogues comprise a modified cytosine ring which is connected to 
either a ribose or deoxyribose moiety, and, therefore, can be integrated into DNA or RNA, 
replacing cytosines.  When incorporated into DNA, during S phase of the cell cycle, they 
covalently bind and inhibit DNMTs on DNA strand, inducing cell death or DNA damage [43, 
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44]. Therefore, these compounds can deplete DNMTs, which results in passive loss of 
cytosine methylation in daughter cells after successive DNA replications and, consequently, 
reactivation of epigenetically silenced genes expression [43, 45]. Moreover, lack of DNMTs 
activity induced by drug uptake during DNA synthesis leads to reduction of cytosine 
methylation in the genome [46, 47]. DNMTi can lead to activation of epigenetically silenced 
tumor suppressor genes (TSGs) resulting in cell death, cell cycle arrest, chromatin 
extension and induction of cell differentiation [46-48]. The most well characterized 
nucleoside analogues, 5-azacytidine (Vidaza™) and 5-aza-2'-deoxycytidine (Dacogen™), 
have been widely used in pre-clinical and clinical trials in a broad spectrum of cancer models 
due to their anti-tumorigenic activity [49, 50]. These drugs were developed in 1964 as 
classical cytostatic agents [51], while in the 80’s it was disclosed not only their ability to 
induce cell differentiation in vitro but also their involvement in DNA methylation inhibition 
[52]. The clinical benefit observed in clinical trials for hematologic cancer patients, [53, 54] 
led to the US FDA approval of  5-azacytidine and 5-aza-2'-deoxycytidine in 2004 and 2006, 
respectively, for myelodysplastic syndrome (MDS) treatment [40, 41]. In addition to MDS, 
these compounds are also active against acute myeloid leukemia (AML) and other myeloid 
malignancies [55]. However, both 5-azacytidine and 5-aza-2'-deoxycytidine present several 
limitations in clinical practice, due to their cytotoxic effect at higher doses, instability under 
physiological conditions and short half-life attributable to degradation by hydrolytic cleavage 
and deamidation by cytidine deaminase enzyme [56, 57]. Moreover, high doses of 5-
azacytidine can cause neutropenia and thrombocytopenia [58]. One of the major concerns 
related to these compounds is their lack of specificity which might activate the expression 
of normally silenced genes contributing to tumorigenesis [59]. Nevertheless, a large trial 
with MDS treated patients with lower doses of these agents, showed not only an increase 
in conversion time for leukemia but also improved overall survival (OS) [39]. To improve the 
stability and efficacy of azanucleosides agents, other cytidine analogues have been 
developed, such as zebularine, 5-Fluoro-2’-deoxycytidine, 5,6-dihydro-5-azacytidine, SGI-
110, CP-4200 and Gemcitabine. Zebularine is a deoxycytidine derivate that lacks an amino 
group in position 4 of the pyrimidine ring [60]. This compound stabilizes the binding of 
DNMTs to DNA, thereby trapping the enzyme and preventing its turnover even at other 
sites, resulting in decreased methylation and dissociation of the enzyme-DNA complex  [61]. 
Additionally, zebularine is stable in neutral and acidic aqueous solution, induces minimal 
toxic effects in animals, inhibits cytidine deaminase, and if administered continuously in 
cancer cells, effectively maintains gene demethylation [62]. This demethylating agent was 
also the first nucleoside analogue able to reactivate an epigenetically silenced gene by oral 
administration [62]. Importantly, this compound demonstrated a high selectivity for tumor 
cells [63]. 5-Fluoro-2’-deoxycytidine (FdCyd) is a fluoropyrimidine nucleoside analogue [60] 
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that also forms covalent bindings with DNMTs to produce a suicide complex [64, 65]. Like 
zeburaline, FdCyd is stable in aqueous solution, and less toxic than 5-azacytidine and 5-
aza-2'-deoxycytidine [60]. However, it is rapidly metabolized in vivo by cytidine deaminase 
[66]. To overcome this obstacle, clinical studies showed that co-administration of FdCyd 
with a cytidine deaminase inhibitor, such as tetrahydrouridine (THU), improved its stability 
[67]. 5,6-dihydro-5-azacytidine (DHAC) is a hydrolytically stable 5-azacytidine nucleoside 
due to the saturation of 5,6-double bond which prevents the nucleophilic attack of the 
position 6 by water. This compound is less cytotoxic than 5-azacytidine and 5-aza-2'-
deoxycytidine overcoming their main weaknesses [68]. Similarly to 5-azacytidine, DHAC 
can be incorporated into the RNA and inhibits its synthesis and DNA methylation in human 
cell lines [69]. However, clinical trials with DHAC resulted in low response rate and 
significant side effects, as severe chest pain, and cardiotoxicity [69, 70]. SGI-110 
(guadecitabine) a dinucleotide consisting of 5-aza-2'-deoxycytidine followed by a 
deoxyguanosine, is a largely resistant cytidine deaminase compound that has been 
reported to be effective in DNA methylation inhibition in vitro and in vivo, and that can also 
act as an immune modulator [71, 72]. Importantly, compared to 5-aza-2'-deoxycytidine and 
5-azacytidine, this second-generation hypomethylating drug with improved pharmacology 
and pharmacodynamic effects showed good tolerance, as well as biological activity in 
patients with MDS and AML [73]. It was also demonstrated that this drug protects 5-aza-2'-
deoxycytidine from deamination, increasing its exposure time and metabolic stability [71, 
74]. CP-4200 is an elaidic acid ester analogue of 5-azacytidine that contains a fatty acid 
moiety in order to turn the cellular uptake of the drug less dependent on the nucleoside 
transport systems. This compound had shown significantly higher efficacy comparatively to 
5-azacytidine in an orthotopic mouse tumor model for acute lymphocytic leukemia, and also 
a strong epigenetic modulatory effect in several human cancer cell lines [75]. Gemcitabine 
is a pyrimidine cytosine analogue which acts as an anti-metabolite and have been used in 
chemotherapy [76]. This agent requires intracellular conversion in two active metabolites, 
gemcitabine diphosphate and gemcitabine triphosphate, which in turn can function in two 
ways: by binding to ribonucleotide reductase (RNR) and irreversibly inhibiting it, and/or by 
replacing cytosine during DNA replication [77]. Recently, a newly synthetized cytidine 
analogue, RX-3117 (fluorocyclopentenylcytosine), was described as able to interfere with 
cell division, DNA synthesis and induce cell cycle arrest at G1 phase and apoptosis. RX-
3117 cellular uptake is mediated by the human equilibrative nucleoside transporter (hENT1) 
and requires uridine-cytidine kinase (UCK) to be activated. RNR reduce RX-3117 
diphosphate to deoxyRX-3117 diphosphate, that can be converted to deoxyRX-3117 
triphosphate and subsequently incorporated into DNA molecule, inhibiting DNMTs [78, 79].   
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 Non-nucleoside analogues  
The cytotoxic effects inherent to nucleoside analogues derived from their direct 
incorporation into DNA [64, 80] gave rise to the development and discovery of new 
compounds that can directly bind to the catalytic site of DNMTs without requiring prior 
incorporation into the DNA molecule [81]. Procaine (local anesthetic) and its derivative 
procainamide (anti-arrhythmic drug) are two closely related small molecules able to reduce 
DNA methylation in cancer cells [82, 83]. These agents are thought to directly bind to CpG-
rich sequences, perturbing the interactions between DNMTs proteins and its target sites 
(CpG islands). Procaine was able to reduce 40% of 5-methylcytosine DNA content and 
densely demethylate hypermethylated CpG islands, such as those located in the promoter 
region of the RARβ2 gene with concomitant re-expression. Furthermore, this agent exerted 
growth-inhibitory effects in MCF-7 breast cancer cell line by inducing mitotic arrest [82]. 
Procainamide preferentially inhibits DNMT1 but not DNMT3A and 3B, suggesting a highly 
specific inhibitory effect of this compound [84]. IM25 is a novel and small DNMT1 inhibitor 
derived from procainamide, that was shown to demethylate GSTP1 with lower toxicity 
comparatively with procainamide and 5-aza-2’-deoxycytidine [85]. Hydralazine is a potent 
arterial vasodilator agent that has been recognized as a demethylating agent [86]. However, 
its mechanism of action is not yet well understood. Some authors suggest that this drug 
inhibits DNA methylation, establishing highly stable interactions between its nitrogen atoms 
and the active site of DNMTs [87]. Hydralazine was shown to induce demethylation and 
reactivation of TSG in several cancer models, without significant cytotoxic effects [86, 88]. 
Interestingly, its activity is synergized when combined with valproic acid, an effective short-
chain fatty acid HDAC inhibitor [87-89]. The antibiotic nanaomycin A was recently reported 
as a selective inhibitor of DNMT3B enzyme, with the ability to reduce DNA methylation and 
induce re-expression of Ras-association domain family protein 1 isoform A (RASSF1A) 
TSG in cancer cell lines [90]. Most DNMTi are not specific for a particular DNMT, which may 
favor toxicity. To overcome this issue, two novel small molecules were designed: MG98 and 
RG108. MG98 is a second-generation 20-nucleotide antisense oligonucleotide designed to 
hybridize with the 3'-UTR of human DNMT1 mRNA leading to enzyme downregulation [91]. 
A phase I clinical trial demonstrated that this compound not only inhibited DNMTs in a more 
selective manner but also was well tolerated being associated with lower cell toxicity [92]. 
Despite this DNMT1 inhibitory activity, this compound did not reach a significant response 
in clinical trials [92-94]. RG108 is a synthetic molecule designed to directly inhibit DNMT1 
catalytic domain. This compound blocked DNMT1 without causing enzyme degradation [95] 
and with low cytotoxic effects [96]. Furthermore,  RG108 has been shown to effectively 
reactivate several epigenetically silenced TSGs, without affecting the methylation state of 
centromeric repeats [95, 96]. Disulfiram, a compound with strong thiol-reactive functional 
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groups which attack the thiol group of the reactive cysteine in the active site of the aldehyde 
dehydrogenase enzyme [97], is used in clinical practice for alcohol abuse treatment [98]. 
This compound was recently described as a DNMTi since it was capable of reduce the 
overall levels of 5mC, demethylate and reactivate the expression of epigenetically silenced 
TSGs [99]. The quinoline-based compound SGI-1027 demonstrated inhibitory activity 
against DNMT1, DNMT3A and DNMT3B, possibly by interaction with the DNA substrate 
which results in demethylation and reactivation of TSGs [100, 101]. Several studies 
suggested that non-nucleoside inhibitors are not necessarily less genotoxic and cytotoxic 
than nucleosides analogues. Moreover, these compounds were reported to be less effective 
in the inhibition of DNA methylation and reactivation of gene expression than the nucleoside 
analogues inhibitors [95, 102].  
 
 Natural compounds 
Natural products found in food appears to have antioxidant and anti-tumoral 
properties, as well as may represent a potent class of epigenome-targeted-drugs, including 
isothiocyanates (such as phenethyl isothiocyanate) and polyphenols (like epigallocatechin-
3-gallate, genistein, curcumin and flavanones) [103, 104]. The role of these compounds as 
epigenetic modulators is now a hot topic of investigation (Table 2). Phenethyl isothiocyanate 
(PEITC), found in cruciferous vegetables, induces cellular growth arrest and apoptosis 
[105]. Epigallocathechin-3-gallate (EGCG), derived from green tea, inhibit DNA methylation 
by binding to and blocking the active site of human DNMT1, leading to reactivation of TSGs 
[106]. Genistein, one of the most common and well known isoflavones, was reported to be 
the major anti-cancer constituent of soybean [107]. Several molecular targets were 
attributable to this compound, including estrogen receptor (ER) [108]. Curcumin one of curry 
constituents, has numerous medicinal and anti-cancer properties [109]. Nowadays, 
Curcumin appears as a promising chemopreventive agent able to reverse, inhibit or prevent 
the development of several human malignancies through inhibition of specific molecular 
signaling pathways involved in carcinogenesis [110-112]. Curcumin was reported to induce 
global hypomethylation in MV4-11 leukemia cell line through molecular docking with 
DNMT1 enzyme, suggesting that this compound covalently blocks the catalytic thiolate of 
DNMT1 inhibiting DNA methylation [113]. Flavanones are a subgroup of flavonoids which 
are abundantly found in citrus fruits. Naringenin from grapefruit and hesperetin from 
oranges are the major flavanones and were reported as being able to inhibit DNMTs activity 
[114, 115]. These compounds also demonstrated the ability to induce apoptosis, inhibit 
cancer cell proliferation, invasion and migration by affecting several important signaling 
pathways [116].  
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Table 2 – DNA demethylating potential of natural compounds. 
 
DNMTi in urological tumors: pre-clinical and clinical trials  
Urological tumors harbor several epigenetic alterations, being hypermethylation of 
TSGs the most common and studied one. The panel of the most relevant hypermethylated 
genes in each urological tumor is represented in Figure 5.  
 
Figure 5 - An overview of the most relevant hypermethylated genes in each urological tumor, compiled from the 
referenced cited in the main text. 
In the last decades, several studies reported the clinical usefulness of DNMTi for 
urological tumors therapy. Contrarily to prostate cancer, the role of these agents in the 
Compound Target  Model Results Ref. 
Curcumin DNMT1 Leukemia cell line Global DNA hypomethylation [113] 
DNMT1 Docking-based virtual screening 
and experimental evaluation 
DNA demethylation [117] 
EGCG DNMTs Colon cancer, esophageal 
cancer, and prostate cancer cell 
lines 
DNA demethylation and reactivation 
of gene expression (hMLH1, 
MGMT, p16INKA, and RARβ) 
[106] 
Genistein DNMTs Esophageal squamous cell 
carcinoma cell lines 
DNA demethylation and reactivation 
of gene expression (MGMT, 
p16INKA, and RARβ) 
[118] 
DNMTs Prostate cancer and RCC cell 
lines  
DNA demethylation and reactivation 
of gene expression (BTG3)  
[119] 
DNMTs Prostate cancer cell lines DNA demethylation and reactivation 
of gene expression (p16 and p21) 
[120] 
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remaining urological tumors is still rather unexplored. Pre-clinical and clinical assays 
performed for each urological tumor are reviewed in the next sections, being all the clinical 
trials (completed, terminated or ongoing) summarized in Tables 3, 4, 5 and 6 corresponding 
to each urological tumor model. 
 
 Bladder Cancer 
Bladder cancer (BlCa) is the ninth most common malignant tumor worldwide and its 
incidence is 3 times higher among men than women, representing the 4th and the 11th 
most common cancer, respectively [121]. However, for unknown reasons, women have 
higher mortality rates than men [122]. Urothelial cell carcinoma (UCC) is the most common 
histological subtype of BlCa representing about 90% of all cases, while the remaining 10% 
are non-urothelial subtypes, as squamous cell carcinoma or adenocarcinoma. Depending 
on the degree of cancer cells histological differentiation, UCC can be classified in low-grade 
and high-grade. Besides, based on invasion level of muscular bladder wall, UCC can also 
be classified as nonmuscle invasive BlCa (NMIBC) and muscle invasive BlCa (MIBC) [123]. 
Despite more than 80% of UCC are superficial lesions with a favorable prognosis, these 
lesions tend to frequently recur. This relapsing nature of BlCa makes it one of the most 
expensive human malignancies to treat [124]. A deeply invasive BlCa is often correlated 
with fatal outcome [125]. Low-grade UCC is primarily managed by bladder-sparing 
techniques as endoscopic resection and intravesical chemotherapy. While in muscle-
invasive phenotype, radical cystectomy with neoadjuvant chemotherapy are the first line 
treatment, patients with advanced disease are treated with systemic cisplatin-based 
chemotherapy regimens [126]. However, these therapies are not curative, and this 
aggressive phenotype can develop resistance to chemotherapeutic drugs resulting in 
treatment failure. Concerning epigenetic alterations, high-grade UCCs present higher 
hypermethylation levels and upregulation of several microRNAs (miRNAs), when compared 
with low-grade UCCs [127, 128]. The main difference between low- and high-grade UCC 
seems to be the quantity of aberrant hypermethylation instead of the specific targets. 
Epigenomic profiling has revealed that 10% of the loci in low-grade UCC displayed aberrant 
DNA methylation patterns, contrarily to high grade noninvasive and invasive UCC that have 
over 20% and 30%, respectively [129-131]. Biallelic expression of the imprinted gene IGF2 
and imprinted maternally expressed transcript H19 were described in around 20% of BlCa 
[132]. Hypomethylation of LINE-1 gene was correlated with an increased risk of BlCa and 
could be a potential biomarker for BlCa diagnosis and treatment [133]. Several 
hypermethylated genes, namely APC, ARF, CDKN2A, DAPK, LAM-5 and RASSF1A have 
been proposed as detection markers for BlCa [134-136]. SERPINB5 (gene that encodes for 
| INTRODUCTION  
14 
maspin) expression is higher in normal urothelium, preserved in superficial BlCa, but is 
significantly diminished in invasive carcinomas. This low maspin expression is correlated to 
gene hypermethylation and with increased tumor cell growth in vivo [137, 138]. Moreover, 
a genome wide approach, led to identification of  a panel of three genes, GDF15, TMEFF2 
and VIM, that accurately detect this neoplasm [139]. Importantly, the methylation pattern of 
APC, CDH1 and RASSF1A genes are also significantly correlated with prognostic 
parameters [140], and disease progression [128]. The increased methylation levels of ARF 
and RASSF1A can be a predictor of tumor stage and/or grade with potential clinical benefit. 
Furthermore, BCL2 methylation levels were significantly associated not only the with  
disease stage but also with tumor grade [136].   
 
1.1.  Pre-clinical Studies 
Concerning pre-clinical assays in BlCa, the majority of them evaluated the efficacy 
of nucleoside inhibitors as potential anti-tumor agents for BlCa. Regarding exposure of BlCa 
cells to 5-azacytidine, it was demonstrated that this compound induced downregulation of 
DNMT3A/3B expression and reversed the hypermethylation with concomitant re-
expression of hepaCAM gene. In addition, 5-azacytidine inhibited 
proliferation of BlCa cells and arrested cell cycle at G0/G1 phase. Likewise, tumor growth of 
nude mice was markedly reduced after treatment with this compound [141]. 5-Azacytidine 
combined with the histone deacetylase inhibitor Trichostatin A (TSA) decreased cell 
proliferation by attenuating the expression of DNMT1 in canine invasive urothelial 
carcinoma cells. Additionally, this combination caused a noticeable increase in p16 protein 
expression by demethylation of its gene promoter region [142]. A recent pre-clinical study 
showed a unidirectional cross-resistance of cisplatin-resistant UMUC3 cells to docetaxel. 
However, pre-treatment of BlCa cell lines (UMUC3, T24 and TCSSUP) with 5-azacytidine 
resulted in enhanced sensitivity to chemotherapeutic drugs (cisplatin and docetaxel) by 
demethylating and up-regulating epigenetically silenced genes involved in apoptotic 
pathway [143].  Exposure of T24 cells to different concentrations of 5-aza-2’-deoxycytidine 
resulted in increased levels of maspin mRNA and protein in a dose dependent manner. In 
addition, proliferation, migration and invasion of T24 cells were significantly inhibited, 
whereas the apoptosis was greatly increased. All these effects were associated with the 
activation of caspase-3, decreased ratio of Bcl-2/Bax,  and reduced expression of cyclin D1, 
VEGF-C, MMP-2 and MMP-9 [138]. B-cell translocation gene 2 (BTG2) is downregulated in 
human BlCa samples and this appear to be due the boundary of DNMT1 to BTG2 locus 
suppressing gene expression via down-regulation of its transcription factor, Sp1. 5-aza-2'-
deoxycytidine induced BTG2 demethylation and re-expression by inhibiting DNMT1 
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expression. Thus, this increased BTG2 expression significantly reduced the highly 
malignant EJ cells tumorigenesis and invasiveness in vitro, together with induction of G2/M 
arrest [144]. Additionally, 5-aza-2’-deoxycytidine suppressed cellular growth in several BlCa 
tumor cell lines. In fact, this drug induced demethylation and upregulation of CDKN2A gene 
which was associated with G1 cell cycle arrest. Importantly, exposure of T24 cells to 5-aza-
2’-deoxycytidine prior to injection into nu/nu mice decreased the rate of tumor growth and 
lead to reactivation of CDKN2A [145]. The combination of 5-aza-2’-deoxycytidine with 
cisplatin inhibited proliferation through inducing G2/M cell cycle arrest and apoptosis of UCC 
cell lines. Moreover, 5-aza-2'-deoxycytidine enhanced not only the cisplatin-induced 
upregulation of caspase activity but also its anti-proliferative effect by increasing the 
population of cells at sub-G1 and G2/M phases [146]. Recently, a study involving several 
BlCa cell lines reported an association between HOXA9 promoter methylation status and 
response to cisplatin-based chemotherapy. BlCa cells resistant to cisplatin chemotherapy 
with high HOXA9 promoter methylation levels were sensitized to cisplatin by 5-aza-2'-
deoxycytidine [147]. Interestingly, the combination of four drugs, namely gemcitabine, 
cisplatin, 5-aza-2'-deoxycytidine and TSA, inhibited the canonical Wnt/β-catenin pathway 
and diminished cell proliferation through repression of DNA methylation. Furthermore, the 
anti-apoptotic gene BCL2L1 was significantly downregulated [148]. A comparative study 
with 5-aza-2'-deoxycytidine and zebularine reported that these two agents equally retarded 
the cell growth of BlCa cell lines (T24 and RT4), but contrarily to T24 cell line, whose 
exposure to zebularine resulted in the same proportion of Doubling-Time (DT) prolongation 
as 5-aza-2'-deoxycytidine (79.8 vs 79.6%), RT4 cell line DT was higher when treated with 
5-aza-2'-deoxycytidine (66.4 vs 17.5%). Moreover, these two compounds diminished the 
methylation index and concomitantly re-expressed APAF-1 gene [149]. Exposure of BlCa 
cell lines to zebularine resulted in an effective demethylation of the CDKN2A gene and 
prevented gene resilencing over extended time periods. Furthermore, zebularine induced a 
complete depletion of DNMT1, but not DNMT3A and 3B proteins in T24 cells.  Interestingly, 
sequential exposure of these cells to an initial dose of 5-aza-2’-deoxycytidine (1 µM) 
followed by a low dose of zebularine (50 µM)  prevent CDKN2A remethylation and 
resilencing [150]. Concerning SGI-110, it was reported as an in vivo effective demethylating 
drug that reduced tumor growth in human BlCa xenografted mice and induced CDKN2A 
expression by decreasing DNA methylation levels [71].  Currently, there are no available 
data regarding to clinical trials with demethylating drugs in BlCa (Table 3).  
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Table 3 – Clinical Trials of DNMT inhibitors in Bladder Cancer. 
DRUG PHASE (ID) STATUS SCHEDULE OUTCOME REF. 
5-Aza-2’-
deoxycytidine 
I 
(NCT00030615) 
 
Completed 
Advanced BlCa patients (n=24) 
received daily escalating doses of 5-
aza-2'-deoxycytidine for 4 weeks. 
Courses repeated every 6 weeks in 
the absence of disease progression 
or unacceptable toxicity. 
Data not available [151] 
CC-486 with 
Carboplatin or  
Paclitaxel 
protein bound 
particles (ABI-
007) 
I 
(NCT01478685) Completed 
CC-486 (oral azacytidine) was 
administered orally at doses between 
100-300 mg daily for either 14 or 21 
days. Carboplatin was given by 
intravenous (IV) infusion once every 
21 days. ABI-007 was administered 
by intravenous (IV) infusion on two of 
every three weeks at a dosage of 
100 mg/m2. 
Data not available [152] 
FdCyd and THU II (NCT00978250) Recruiting 
Both drugs will be administrated over 
28-day cycles through a vein for 
about 3 hours each day on days 1, 5 
and 8, 12 of each cycle. Patients 
may continue to receive FdCyd and 
THU if their cancers does not grow, if 
they do not have too many side 
effects, and if they are willing to do 
so. 
Data not available [153] 
RX-3117 I/II (NCT02030067) Recruiting 
Phase I study intend to determine the 
maximum tolerated dose of RX-3117. 
The enrolled subjects (n=72) will be 
treated in a dose expansion followed 
by a 2-stage Phase 2 study for over 
8 cycles of therapy. Each cycle will 
last 4 weeks. RX-3117 will be 
administered 3 times each week for 3 
weeks follow by 1-week rest. All 
subjects will be followed for at least 
30 days after the last dose. 
Data not available [154] 
 
 
 Kidney Cancer 
Renal Cell Carcinoma (RCC) is one of the 10 most common malignancies in the 
developed world, with incidence rates steadily increasing. Incidence predominates in men 
with a male to female ratio of 1.5:1.0 [2]. RCC is the most common type of kidney cancer 
(~85%) and present an heterogeneous histology, genetics and clinical behavior [155]. 
Benign tumors comprise papillary adenoma, oncocytoma, metanephric adenoma and 
adenofibroma [155]. Malignant tumors are classified in three most common subtypes 
namely, clear cell renal cell carcinoma (ccRCC) (65-70%), the most aggressive phenotype, 
papillary renal cell carcinoma types 1 and 2 (pRCC) (15-20%), and chromophobe renal cell 
carcinoma (chRCC) (5-10%), the less aggressive [156]. At early disease stages, RCC is 
clinically silent [157]. However, owing to the improved sensibility of imaging techniques, the 
detection of incidentally small and low-stage RCCs has increased. Nevertheless, locally 
advanced disease and distant metastasis are still diagnosed in a notable proportion of 
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patients [158, 159]. Surgery is the standard treatment for RCC patients [158]. Advanced 
RCC patients are highly resistant to conventional chemotherapy partly due to the 
overexpression of the P-glycoprotein (P-gp) found in 76% of the tumors [160, 161]. 
Therefore, targeted therapy with tyrosine kinase inhibitors (TKIs) is the first-line therapy for 
advanced RCC [158]. Unfortunately, this therapeutic approach is not curative and 
eventually all patients will become resistant to TKIs being the prognosis of metastatic RCC 
extremely poor, with 5-year survival rate of only 5-10% [162, 163]. Several TSGs have been 
reported to be inactivated by promoter hypermethylation in RCC, namely, genes encoding 
for APC, CDH1, RARβ2, RASSF1A, TIMP3 and von Hippel-Lindau (VHL), [164-168]. It has 
been reported that in about 20-30% of sporadic ccRCC, VHL function is lost due to 
hypermethylation of a CpG island in the promoter region of the gene [169, 170]. RASSF1A 
silencing by promoter methylation was proposed as a marker not only for early detection, 
but also for surveillance or disease monitoring [171]. This gene appears to be methylated 
in about 59% of ccRCC and 75% of pRCC [172]. The ubiquitin carboxyl-terminal esterase 
1 (UCHL1) gene, a TSG involved in regulation of cellular differentiation, is silenced by 
promoter hypermethylation in RCC patients and is correlated with poor prognosis [173]. The 
elevated methylation frequency of Wnt antagonists family (SFRPs, DKKs and WIF1) in 
serum DNA from RCC patients was associated with a higher tumor grade, suggesting that 
these genes could be putative progression markers [174]. Recently, the pro-apoptotic gene 
ASC/TMS1 was found downregulated by promoter hypermethylation in six RCC cell lines 
and in 41,1% of RCC tumors compared to normal controls. Importantly, hypermethylation 
of this gene was correlated with higher tumor nuclear grade. Besides that, in other cancer 
models, knockdown of ASC/TMS1 reduced cancer cell sensitivity to chemotherapeutical 
drugs. These data suggest that this gene could be a relevant diagnostic and therapeutic 
biomarker [175, 176]. Several other genes were reported as frequently hypermethylated in 
RCC samples compared to normal tissue, namely APAF-1, BTG3, Gamma-catenin, GATA-
3, HOX-B-13, and KILLIN [177].  
 
2.1.  Pre-clinical Studies 
5-aza-2’-deoxycytidine suppressed the canonical Wnt/β-catenin pathway and 
induced apoptosis of Caki-2 cell line through demethylation and re-expression of SFRP2 
and downregulation of p-GSK3β protein [178]. This DNMTi was also able to demethylate 
and re-express ABCG2 and ASC/TMS1 genes in RCC cell lines [175, 179]. Recently, it was 
demonstrated that 5-aza-2’-deoxycytidine was able to decrease the proliferation of several 
RCC cell lines (ACHN, Caki-1, Caki-2 and A-498) mainly by inducing cell cycle arrest at 
G2/M in a dose-dependent manner. This effect might be related to the suppression of p38-
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NF-kB pathway phosphorylation by this demethylating agent [180].  Exposure of RCC1.18 
primary cell lines to 1 µmol/L of this demethylating inhibitor during 96 hours was capable to 
induce RARβ2 expression [181]. Furthermore, 5-aza-2’-deoxycytidine re-expressed VHL 
both in RCC cell lines and in xenograft murine tumors and significantly reduced tumor size 
of ccRCC xenograft mice [182]. A recent report, that evaluated the methylation profile of 
drug target genes in RCC, demonstrated that 1 µM of 5-aza-2’-deoxycytidine decreased 5-
methylcytosine content in genomic DNA of Caki-2 cells leading to organic cation transporter 
2 (encoded by SLC22A2 gene) re-expression. Moreover, exposure to this compound 
resulted in demethylation and upregulation of 33 out of the 55 tested SLC drug transporters. 
As these transporters are associated with sensitivity to platinum chemotherapy, the 
combination of 5-Aza-2′-deoxycytidine with cisplatin was investigated. Remarkably, this 
drug combination was more effective in apoptosis induction than either drug alone [183]. 
Treatment of murine renal cell carcinoma (Renca) cells with 5-aza-2’-deoxycytidine resulted 
in re-expression of TβR-II at both mRNA and protein levels. This allowed the restoration of 
Renca cells sensitivity to TGF-β by an increase in phosphorylation of SMAD2 which is a 
consequence of TGF-β receptors activation [184]. The exposure of RCC cell lines to 5-aza-
2’-deoxycytidine induced reactivation of the pro-apoptotic RASSF1A gene silenced by 
promoter hypermethylation  [185]. Recently, it was demonstrated that 5-aza-2’-
deoxycytidine significantly induced global genomic demethylation of RCC cells with 
restoration of APAF-1 expression at both mRNA and protein levels. Moreover, 5-aza-2’-
deoxycytidine promoted the apoptotic effect of cisplatin in ACHN cells [186]. This compound 
was also able to induce mRNA and protein expression of UCHL1 gene in several RCC cell 
lines [187]. In fact, exposure of RCC cell lines to 5-aza-2’-deoxycytidine decreased the 
methylation levels with concomitant re-expression of DACH1, DKK1, DLK1, GATA3, 
GREM1, KILLIN, KRT19, PCDH17, Rap1GAP, SFRP2, SFRP5, TCF21, TU3A and WIF-1 
[188-201]. Interestingly, exposure of RCC cell lines to 5-aza-2'-deoxycytidine and 
zebularine effectively inhibit tumor cell growth and re-expressed APAF-1 and DAPK-1 
mRNA transcripts. Remarkably, zebularine was more effective in achieving a DT 
prolongation than 5-aza-2'-deoxycytidine in a RCC p53 mutated cell line [149]. The natural 
compound Genistein used in combination with 5-aza-2'-deoxycytidine significantly 
decreased BTG3 (TSG) promoter methylation reactivating its expression. Besides that, this 
combination decreased DNMTs and methyl-CpG-binding domain 2 (MBD2) activity and 
increased histone acetylation [119]. Exposure of human papillary ACHN cell line to 5-aza-
2’-deoxycytidine synergistically augmented the anti-proliferative effects of IFN-α e IFN-β. In 
addition, this compound not only increased more than 10 times the expression of IFN 
response genes but also induced demethylation of the apoptosis-associated IFN response 
gene XAF1 promoter. Interestingly, MG98 also defeated the resistance to IFN-induced 
| INTRODUCTION 
19 
apoptosis. Either 5-aza-2’-deoxycytidine or MG98 depleted DNMT1 enzyme leading to 
reactivation of cancer-testis antigens MAGE and RAGE in ACHN cells which might be 
relevant for immune modulation [202]. In a pre-clinical assay, exposure of RCC cell lines 
(Caki-1, 786-O and A498) to 5-aza-2’-deoxycytidine enhanced the cytotoxicity of vinblastine 
(VBL), one classical cytotoxic drug against RCC. 5-aza-2’-deoxycytidine led to 
demethylation and re-expression of connexin 32 (Cx32) which directly contributed to 
downregulation of P-gp by activation of c-Jun NH2-terminal kinase (JNK). These results 
suggest that re-expression of Cx32 increases RCC cells response to VBL [203]. Notably, 
the co-treatment of Caki-1 xenograft mice with 5-aza-2’-deoxycytidine and VBL led not only 
to suppression of tumor volume and weight but also reduced the expression of P-gp, Bcl-2 
and cyclin B1. This combined effect appear to be mediated by the accumulation of 
intracellular VBL and by apoptosis and cell cycle arrest induction [204]. Likewise, 
combination of 5-aza-2'-deoxycytidine with paclitaxel (PTX) synergistically inhibited RCC 
cell growth. Both drugs suppressed RCC cell proliferation by inducing G2/M cell cycle arrest 
and PTX also enhanced tumor cell apoptosis in a dose-dependent manner. Thus, this 
synergistic growth suppression of RCC cells suggests that this DNMTi could remarkably 
increase the susceptibility of RCC to PTX [205]. A green tea extract composed by flavan-3-
ols and EGCG, strongly inhibited the growth of A-498 and 769-P cell lines in a 
concentration-dependent manner, showing to be an effective anti-cancer agent for RCC 
[206]. Interestingly, oral administration of RX-3117 reduced tumor cell growth of Caki-1 
xenograft mice more efficiently than gemcitabine [207].  
 
2.2.  Clinical Trials 
Monotherapy with 5-aza-2’-deoxycytidine was scheduled in a phase I study at doses 
from 2.5 to 20 mg/m2 on days 1-5. Even though 5-aza-2’-deoxycytidine decreased DNA 
methylation both in tumor and in peripheral blood mononuclear cells (PBMCs), there was 
no correlation between these two parameters. However, this agent induced apoptosis and 
increased CTR1 (copper transporter) expression through methylation-independent 
mechanisms [208]. A phase I clinical trial that combined 5-aza-2'-deoxycytidine, daily 
subcutaneously injected during 5 days at weeks 1 and 2 of a 12-week cycle, with high-dose 
interleukin-2 (600,000 IU/Kg), administered intravenously 14 times every 8 hours, resulted 
in stable disease in 3 of the 5 RCC patients enrolled. Grade 4 neutropenia was observed 
[209].  Another phase I trial, that enrolled 55 patients with advanced disease, from which 
two were RCC patients, combined 5-azacytidine subcutaneously administered with orally 
valproic acid. One RCC patient presented stable disease for 6 months with a significant 
increase in histone acetylation. Grade 3 and 4 toxicities were reported [58]. In contrast, a 
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phase I clinical trial with 5-azacytidine and sodium phenylbutyrate that evaluated three 
refractory kidney cancer patients did not reach clinical benefit or stable disease. However, 
one patient presented a significant decrease of DNMTs activity and the remaining two 
patients achieved an increase in histone acetylation [210].  Finally, in a phase I/II trial 
(NCT00003890) that enrolled 20 metastatic renal carcinoma patients, was assessed the 
anti-tumor activity of MG98. This compound was intravenously administered at a dose of 
360 mg/m2 twice weekly for three consecutive weeks out of four. The most common 
symptomatic toxicities were rigors, fatigue, fever, and nausea. Unfortunately, the results did 
not show a conclusive pattern of decreased DNMT1 activity in PBMCs post MG98 treatment 
[94]. However, a recent clinical study with advanced RCC patients demonstrated a great 
tolerance for combination of MG98 and IFN-α-2β in an intermittent schedule rather than 
continuous. Indeed, one patient showed a partial response, one had symptomatic 
improvements and eight patients achieved stable disease after combined intermittent 
treatment [211]. 
Table 4 – Clinical Trials of DNMT inhibitors in Kidney Cancer. 
DRUG PHASE (ID) STATUS SCHEDULE OUTCOME REF. 
5-Aza-2’-
deoxycytidine I Completed 
Refractory RCC patients 
(n=3) received intravenously 
5-aza-2’-deoxycytidine from 
2.5 to 10 mg/m2 on days 1-5, 
and from 8 to 12, or 15 to 20 
mg/m2 on days 1-5. Each 
cycle lasted four weeks. 
Relative reduction of 
tumor size; 
Increased tumor 
apoptosis; 
Reduction of DNA 
methylation in both 
tumor and PBMC but 
without correlation 
between them; 
Increased expression 
of CTR1. 
[208] 
5-Aza-2’-
deoxycytidine 
and Interleukin-2 
I Completed 
Renal cancer patients (n=5) 
received subcutaneous 5-
aza-2’-deoxycytidine daily x 5 
days on weeks 1 and 2 of a 
12-week cycle. High-dose IL-
2, consisting of two cycles of 
IL-2 600,000 IU/kg 
intravenously every 8 hours’ x 
14 doses separated by a 2-
week break, was 
administered starting on week 
3. 
Decitabine was escalated 
from 0.1 to 0.25 mg/kg. 
 
Global DNA 
demethylation. 
Up-regulation of 
immunomodulatory 
genes. 
Three of five evaluable 
patients presented 
stable disease. 
Grade 4 neutropenia 
was observed. 
[209] 
5-Aza-2’-
deoxycytidine 
and Interferon 
alfa-2β 
II 
(NCT00561912) Terminated 
Patients with advanced RCC 
(n=2) received 5-aza-2'-
deoxycytidine 15 mg/m2 
intravenously daily over 1h for 
5 days plus Interferon Alfa-2b 
0.5 million units 
subcutaneously twice daily 
continuously, on day 1 cycle 
3. Each cycle was 28 days 
long. 
Terminated due to low 
accrual. [212]   
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Table 4 - Clinical Trials of DNMT inhibitors in Kidney Cancer (cont.). 
DRUG PHASE (ID) STATUS SCHEDULE OUTCOME REF. 
5-Azacytidine 
and Valproic 
Acid 
I Terminated 
5-Azacytidine was 
administered subcutaneously 
daily for 10 days in patients 
with advanced cancers 
(n=55), two of them with 
RCC. Cycles were 28 days 
long and 5-azacytidine was 
administered at 20 mg/m2. 
One of the two treated 
RCC patients 
achieved a 6 months’ 
stable disease. Data 
not available for 
decrease in 
methylation but it was 
observed histone 
acetylation. 
Grade 3 and 4 
toxicities were 
observed. 
[58] 
5-Azacytidine 
and Sodium 
phenylbutyrate 
I Completed 
5-azacytidine subcutaneously 
and sodium phenylbutyrate 
(continuous intravenous 
infusion) were administered in 
refractory kidney cancer 
patients (n=3) regarding three 
different dose regimens 
during 48 cycles in the 27 
advanced solid tumors 
patients. 
No clinical benefits 
were seen in the three 
tested regimens for 
RCC patients.  
Reduced tumor tissue 
methyltransferase 
activity in one patient 
and increased histone 
acetylation in two 
patients. 
Grade 3 and 4 
neutropenia were 
observed. 
[210] 
5-Azacytidine 
and Interferon-α-
2β 
I 
(NCT00217542) Completed 
Patients (n=42) received 
azacytidine subcutaneously 
once daily on days 1 to 4 and 
15 to 17 and recombinant 
interferon alfa-2b 
subcutaneously on specific 
days during course 1. 
Beginning in course 2 and for 
all subsequent courses, 
patients received azacytidine 
subcutaneously once daily on 
days 1-3 and 15-17 and 
interferon alfa-2b 
subcutaneously on specific 
days. Treatment repeated 
every 28 days for up to 12 
total courses in the absence 
of disease progression or 
unacceptable toxicity. 
Data not available [213] 
5-Azacytidine 
and 
Bevacizumab 
I/II 
(NCT00934440) Unkown 
All patients (n=23) in phase I 
and II received bevacizumab 
at the standard dose of 10 
mg/kg every 2 weeks and the 
doses were administered at 
specific times. 5-azacytidine 
was administered in different 
dose levels for each study 
phase (I/II). 
Data not available [214] 
MG98 I/II (NCT00003890) Completed 
Untreated patients (n=17) 
with measurable metastatic 
renal carcinoma received 
MG98 360 mg/m2 intravenous 
over 2 hours twice weekly for 
3 weeks. Courses were 
repeated every 4 weeks. 
No conclusive pattern 
of decreased DNMT1 
activity was detected 
after MG98 treatment. 
Toxicities was 
experienced including 
fatigue, fever, and 
nausea. 
[94] 
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Table 4 – Clinical Trials of DNMT inhibitors in Kidney Cancer (cont.). 
DRUG PHASE (ID) STATUS SCHEDULE OUTCOME REF. 
MG98 and 
Interferon-α-2β 
Study phase not 
provided Completed 
Patients with advanced RCC 
(n=19) were divided in 2 
groups: 10 received a 
continuous regimen and 9 
received an intermittent 
regimen twice weekly. In the 
first group, patients received 
MG98 in two 7-day continuous 
infusions every treatment 
week followed by a week of 
rest in each cycle. In the 
intermittent group, patients 
were treated with a 2h 
intravenous infusion of MG98 
twice per week for three 
weeks with the last cycle week 
of rest. Additionally, both 
groups received interferon-α-
2β subcutaneously three days 
per week with an initial dose of 
12 MIU/day or 9MIU/day. 
Interferon-α-2β 9 MIU 
plus MG98 125 mg/m2 
for a continuous 
schedule and 
interferon-α-2β 9 MIU 
plus MG98 200 mg/m2 
for an intermittent 
schedule were 
considered the 
maximum tolerable 
doses. The first 
showed 2 out of 7 
dose-limiting toxicities, 
including fever and 
thrombocytopenia. 
One partial response 
and eight stable 
disease were 
achieved. 
[211] 
 
 Prostate Cancer 
PCa is the second most commonly diagnosed cancer and the fifth leading cause of 
cancer related death in men worldwide [215]. When confined to the organ, which represents 
early stage disease, PCa is curable by radical prostatectomy and/or radiation therapy [216]. 
The use of serum PSA for PCa detection lacks sensitivity and specificity, leading to a 
relatively high frequency of unnecessary prostate biopsies that is an expensive and invasive 
procedure [217]. Consequently, a substantial proportion of patients with indolent tumors is 
overdiagnosed and overtreated, from which several might experience side-effects, such as 
urinary incontinence and erectile dysfunction, without significant clinical benefit [218]. For 
advanced disease, the treatment of choice is Androgen Deprivation Therapy (ADT) which 
aims to reduce the levels of male hormones. Even though the majority of the patients initially 
respond to this therapy, after 18-24 months,  approximately 30% of the cases progress to 
the lethal stage of this disease, designated as Castration-Resistant PCa (CRPC) [219]. 
Despite the possibility of treating these CRPC patients with secondary hormonal therapeutic 
agents, such as abiraterone acetate and enzalutamide, the acquired resistance inevitably 
occurs again after a few months [220]. For metastatic CRPC (mCRPC), chemotherapy with 
docetaxel represents the standard therapy, however, the median time to progression 
remains 6 to 8 months and OS remains less than 2 years [221, 222]. Mitoxantrone alone or  
in combination with prednisone, the radiopharmaceutical radium-223 and the autologous 
cellular immunotherapy sipuleucel T can also be used for mCRPC with a significant survival 
benefit [223]. Unfortunately, none of these agents are curative, strengthening the urgent 
need for investigation of new therapeutic approaches. 
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Epigenetic changes, specially DNA methylation play an important role on PCa 
development and progression [224, 225]. In fact, in PCa, promoter hypermethylation is 
directly involved in silencing of several classic TSGs, such as Androgen Receptor (AR), 
APC, Glutathione S-Transferase Pi 1 (GSTP1), RARβ2, RASSF1A, estrogen genes, cell 
adhesion genes (CD44 and CDH1), cell cycle control genes (CCND2, CDKN1B and SFN) 
and apoptotic genes (PYCARD, RPRM and GLIR1) [226-233]. Methylation of the RASSF1A 
gene promoter was strongly correlated with increased risk of recurrence of PCa, 
aggressiveness and tumor progression [234]. Importantly, progression to CRPC has also 
been linked to AR silencing by hypermethylation which was in fact,  described in 30% of the 
CRPC [235, 236]. GSTP1 aberrant hypermethylation is one of the most frequent alterations 
in PCa since it has been observed in more than 90% of the tumors and about 75% of pre-
invasive prostatic intraepithelial neoplasms [228, 237]. Therefore, it is the most promising 
epigenetic biomarker for detection of this malignant neoplasm [238]. Overall 
hypomethylation occurs either in primary PCa tumors or, most extensively, in metastatic 
disease [239]. Increased tumor stage (Gleason Score ≥ 7) has been associated not only 
with wide hypomethylation of the genome but also with promoter hypermethylation of 
several individual loci, including ABCB1, APC, GSTP1, PTGS2, PYCARD, RARβ2 and 
RASSFA1 [228, 240].  
 
3.1.  Pre-clinical Studies 
Numerous pre-clinical assays were performed in order to assess the utility of DNMTi 
for PCa treatment.  Gravina et al, showed that when PCa cell lines were exposed to chronic 
administration (20 days) of 5-azacytidine, a significant decrease in tumor cell proliferation 
with significant increase in AR and PSA protein levels were achieved. Furthermore, 
following 5-azacytidine chronic treatment, PCa cell lines increased their sensitivity to the 
apoptotic effects of bicalutamide, an anti-androgen used in clinical [241]. Besides that, 
restoration of AR also sensitized xenograft models of CRPC to this anti-androgen [242]. 
One of the major obstacles for CRPC treatment is the development of chemoresistant 
tumors. Taking this into account, a pre-clinical assay evaluated the role of 5-azacytidine in 
association with docetaxel and cisplatin in aggressive PCa models. The results 
demonstrated a significant reduction of tumor cell proliferation, induction of apoptosis and 
sensitization of xenografts to docetaxel and cisplatin treatments [243]. PCa cells (DU145) 
exposure to 5-aza-2’-deoxycitidine increased the level of plasmonigen activator inhibitor-1 
(PAI-1) transcript in DU145 and restored the pro-inflammatory cytokines effects [244]. 
Moreover, 5-Aza-2’-deoxycitidine led to a significant suppression of cell proliferation, 
induction of cell death, and demethylation of GSTP1 promoter, with associated protein re-
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expression [245]. Recently, exposure of PCa cell lines to 5-aza-2’-deoxycytidine resulted in 
the re-expression of KAI1, a metastasis suppressor gene,  found hypermethylated in PCa  
[246]. 5-aza-2’-deoxycitidine was able to decrease PCa cell stemness and induce a more 
differentiated status. In vitro and in vivo assays demonstrated that AR re-expression 
associated with the reversion of its methylation pattern led to suppression of PCa stem cells 
self-renewal, with a consequent decrease in tumorigenesis [247]. Likewise, in DU145 cell 
line, co-treatment with 5-aza-2’-deoxycytidine and TSA effectively re-expressed AR [248]. 
Contrarily, restoration of ASC/TMS1 expression in LNCaP cells was only achieved with 5-
aza-2’-deoxycytidine while TSA did not increase gene expression [249].  Fialova et al. 
combined 5-aza-2’-deoxycitidine with a histone deacetylase inhibitor (sodium butyrate, 
NaB) and found a significant decrease of cell viability, as well as site-specific demethylation 
at the AR promoter region followed by gene re-expression and increased acetylation of 
histones H3 and H4 [250]. When combined with the chemotherapeutic agent PTX, 5-aza-
2’-deoxycitidine enhanced the apoptotic effects and the arrest at G2/M cell cycle phase of 
this drug. This treatment strategy achieved synergistic growth suppression in all PCa cell 
lines, and could be an alternative for clinical management of this disease [251]. Likewise, 
the combination of cisplatin with 5-aza-2’-deoxycitidine resulted in a great synergy in 
triggering apoptotic death of DU145 cells [252]. Recently, a novel 5-aza-2’-deoxycitidine 
formulation based on the use of engineered erythrocyte (Erythro-Magneto-Hemmagglutinin 
Virosomes) drug delivery system which aims to reduce the incidence of toxicity on healthy 
tissues was described. This novel magnetic EMHV DDS improved the stability of the carried 
drug and exhibited high efficiency in confining its delivery at the site of action, in vivo. 
Moreover, it induced a significant tumor mass reduction in PCa xenografts models at a 
concentration which is 700-fold lower than the normal therapeutic dose. This innovative 
approach might be a good option for solid tumors treatment [253]. Concerning, zebularine 
not only was required a 100-fold higher dose than 5-aza-2’-deoxycitidine to inhibit cell 
proliferation but it was also less potent inducing cell death, and failed to restore GSTP1 
protein expression [245]. On the other hand, zebularine was able to restore sensitivity of 
PCa cells to the DNA minor groove binder brostallicin, which correlated with re-expression 
of GST-pi and GST-mu, in vitro and in vivo [254]. Procainamide led to reversion of GSTP1 
hypermethylation with concomitant restoration of gene expression not only in LNCaP cell 
line but also in xenograft tumors of athymic nude mice [83]. Regarding RG108, it induced 
dose and time dependent growth inhibition and apoptosis of PCa cell lines. This compound 
repressed DNMT activity and expression and reduced global DNA methylation of androgen-
responsive PCa cell lines. Furthermore, chronic treatment (14 days) with RG108 
significantly decreased promoter methylation levels of GSTP1, APC and RARβ2, although 
mRNA re-expression was only succeeded for GSTP1 and APC [255]. Exposure of PCa cells 
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to hydralazine led to cell growth and invasion inhibition and apoptosis induction. Moreover, 
this compound also induced cell cycle arrest and DNA damage. Additionally, the exposure 
of PCa cells to hydralazine decreased DNMT1, DNMT3A and DNMT3B mRNA levels and 
also DNMT1 protein levels, which might be linked to the significant decrease in GSTP1, 
BCL2 and CCND2 promoter methylation levels and concomitant transcript re-expression. 
Importantly, hydralazine restored AR expression, with upregulation of its target p21 in 
DU145 cell line. The attenuated malignant phenotype of PCa cells was also associated with 
EGFR signaling pathway disruption [256]. Disulfiram demonstrated a dose-dependent 
inhibition of DNMT1 activity, promoted PCa cells apoptosis and cell cycle arrest, and 
reduced the global 5mC content. This compound also led to re-expression of APC and 
RARβ2 genes [99]. Besides that, it was able to inhibit PCa cell proliferation by re-expressing 
estrogen receptor-β (ER-β) mainly through inhibition of DNMT activity [257]. Likewise, 
Gemcitabine functionally inhibited DNA methyltransferase activity in both nuclear extract 
and recombinant protein, reactivating several epigenetically silenced genes, including 
GSTP1, IGFBP3 and RASSF1A. This compound also destabilized DNMT1 protein in PCa 
cell lines (LNCaP, 22Rv1 and DU145).  Moreover, it demonstrated a similar activity when 
compared to 5-aza-2’-deoxycitidine and at significantly lower concentrations relatively to 
those achieved in the treatment of patients with solid tumors [258]. SGI-1027 also depleted 
DNMT1 expression in LNCaP cells [100]. Furthermore, this compound and two analogues 
(paralmeta and metalmeta) were able to inhibit cell proliferation and viability of PC-3 cell 
line [259]. Recently, the DNMT inhibitory effect of 1120 small organic compounds was 
evaluated and the 12 most potent hits were selected for cytotoxicity tests in DU145 cell line. 
Notably, most of the compounds revealed inhibitory activity at low micromolar 
concentrations and with low cytotoxicity [260]. Mahanine, a plant-derived carbazole alkaloid, 
was able to restore RASSF1A expression in LNCaP and PC-3 cell lines. This might be 
related to downregulation of DNMT1 and DNMT3B enzymes activity via inactivation of AKT 
pathway [261, 262]. One study comparing non-nucleoside analogue inhibitors, including 
hydralazine and procainamide, with the nucleoside analogue 5-aza-2’-deoxycitidine 
demonstrated that 5-aza-2’-deoxycitidine was considerably more effective in demethylating 
and reactivating TSGs in PCa cell lines than the other non-nucleoside inhibitors [102]. 
Micromolar concentrations of natural compounds were able to inhibit DNMT, MBD and 
HDAC activity, reactivate methylated-silenced TSGs, induce histone acetylation, and alter 
nucleosome positioning in PCa cell lines [115, 263-265]. Regarding genistein, it was shown 
that this compound was able to reverse promoter methylation of GSTP1, RARβ2 and 
RASSF1A with concomitant gene reactivation and protein expression in PCa cell lines 
(LNCaP and PC-3) [118, 266]. Likewise, this compound induced downregulation of DNMTs 
in PCa cells, reducing ER-β promoter methylation with concomitant increase in its 
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expression [267]. A recent study reported that the combination of genistein with daidzein, 
two soy isoflavones, resulted in a synergistic effect on cell proliferation inhibition and 
apoptosis induction of PCa cells [268]. PEITC was able to reduce DNMT protein levels and 
reactivated RASSF1A gene expression in LNCaP cells. Moreover, 5 µM of this compound 
promoted early apoptosis and G2/M cell cycle arrest [269]. Interestingly, the combination of 
PEITC with curcumin, more effectively induced cellular growth arrest and apoptosis, through 
inhibition of protein kinase B and NFkβ pathways, in PCa cell lines and PC-3 xenografts 
than either compound alone [270]. Exposure of TRAMP C1 cells to curcumin resulted in 
reversion of methylation status of Nrf2 promoter, a master regulator of the cellular 
antioxidant defense system, with concomitant gene re-expression [271]. In addition, 5 µM 
of curcumin reversed CpG methylation of Neurog1 promoter region, a cancer methylation 
marker usually highly methylated in PCa and whose expression is also perturbed in LNCaP 
cells [272].  
 
3.2.  Clinical Trials 
A phase I/II clinical trial (NCT00503984) evaluated the combination of 5-azacytidine, 
docetaxel, and prednisone in patients with mCRPC whose disease had progressed during 
or after a docetaxel therapy. In phase I, 5-azacytidine and docetaxel were alternately 
escalated within six combinations of treatment in a standard 3+3 design, being level IV dose 
combination achieved (5-azacytidine 150 mg/m2 daily for 5 days followed by docetaxel 75 
mg/m2 on day 6, every 21 days, and continuous prednisone 5 mg twice daily with growth 
factor support) as the recommended dose. After a safety monitoring review, the phase II 
dose was reduced and patients received 75 mg/m2 daily for 5 days followed by docetaxel 
75 mg/m2 on day 6, every 21 days, and continuous prednisone 5 mg twice daily with growth 
factor support. The overall results demonstrated a reduction in GADD45 methylation at day 
5. This phase I/II trial showed that the combination of 5-azacytidine, docetaxel and 
prednisone with growth factor support is an option for mCRPC patients which provided a 
median progression free survival of 4.9 months for all patients and a median OS of 19.5 
months for 4 of the 22 patients (18 deaths) [273]. An open label phase II study 
(NCT00384839) that enrolled 36 patients evaluated 5-azacytidine effects in men with 
progressive metastatic or non-metastatic CRPC on combined androgen blockade (CAB) 
with PSA-doubling time (DT) < 3 months. The primary endpoint of PSA-DT ≥ 3 months 
during any cycle was achieved in 19 patients. Eleven patients experienced at least one 
PSA-DT ≥ 6 months and nine experienced at least one PSA-DT ≥ 9 months. Twenty-four 
patients (70.6%) demonstrated some slowing of PSA-DT during any cycle of treatment 
compared with baseline, and the median overall PSA-DT during the entire duration of 
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therapy was 2.8 months compared with the baseline of 1.5 months. The median clinical 
progression-free survival for all 36 patients was 12.4 weeks. Grade 3 toxicities included 
fatigue and neutropenia with 4 patients discontinuing the treatment due to toxicity. After 
extending treatment duration, it was observed a trend in decreasing plasma DNA LINE-1 
methylation which significantly correlated with prolongation of PSA-DT [274]. Another phase 
I trial that combined 5-azacytidine and valproic acid enrolled 55 patients with advanced 
malignancies, two of each with PCa. A significant decrease in global DNA methylation and 
induction of histone acetylation with stable disease lasting six months in PCa patients were 
achieved. Neutropenic fever and thrombocytopenia were identified as dose-limiting 
toxicities [58]. Thibault et al., conducted a phase II study with 5-aza-2’-deoxycitidine at 75 
mg/m2 in 14 men with progressive, metastatic PCa recurrent after total androgen blockade 
and flutamide withdrawal. Two of the 12 patients evaluable had stable disease with a time 
to progression of more than 10 weeks. These results disclosed that 5-aza-2’-deoxycitidine 
is a well-tolerated regime with modest clinical activity against CRPC [275]. Recently, a pilot 
clinical trial (NCT01917890) assessed the efficacy of curcumin supplementation in 40 PCa 
patients treated with external beam radiotherapy. Patients were divided in two groups with 
a random selection of those who receive 3g/day curcumin orally (n=20) and a placebo group 
(n=20). Interestingly, patients who received the curcumin regime presented reduced urinary 
symptoms, suggesting that this natural compound could offer radioprotective effects [276]. 
In a dose escalation phase I trial (NCT01118741) with disulfiram in 19 men non-metastatic 
recurrent PCa after local therapy, five patients of two different cohorts achieved a transient 
global demethylation response. However, disulfiram was poorly tolerated in six patients, 
who experienced grade 3 toxicities [277].  
 
Table 5- Clinical Trials of DNMT inhibitors in Prostate Cancer. 
DRUG PHASE (ID) STATUS SCHEDULE OUTCOME REF. 
5-Azacytidine, 
docetaxel and 
prednisone 
I/II 
(NCT00503984) 
 
Terminated 
 
mCRPC cancer patients who 
progressed during or within 6 
months of docetaxel 
chemotherapy, were eligible 
(n=22). 
In phase I, patients received 
the highest dose of 
azacytidine 150 mg/m2 daily 
for 5 days + Docetaxel 75 
mg/m2 on day 6 every 21 
days. 
In phase II, it was used the 
combination of azacytidine 75 
mg/m2 daily for 5 days 
followed by docetaxel 75 
mg/m2 on day 6 along with 
growth factor support and 
fixed prednisone 5 mg since 
day 1 to 21. 
In phase I, grade 4 
neutropenia was 
frequent. In phase II, 
10 of 19 evaluable 
patients showed PSA 
response and 3 of 10 
achieved an objective 
response. 
Significant 
demethylation of 
GADD45A was 
observed. 
 
[273]  
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Table 5 - Clinical Trials of DNMT inhibitors in Prostate Cancer (cont.). 
DRUG PHASE (ID) STATUS SCHEDULE OUTCOME REF. 
5-Azacytidine 
and Combined 
Androgen 
Blockade 
(CAB) 
II 
(NCT00384839) 
 
Completed 
Chemonaïve patients with 
CRPC on CAB and PSA-
doubling time (DT) < 3 months 
were eligible (n=36). 
CBA was continued and 5-
azacytidine 75 mg/m2 was 
administered for 5 consecutive 
days of each 28-day cycle up 
to 12 cycles or until clinical 
progression or intolerable 
toxicities. 
19 of 34 evaluable 
patients attained a 
PSA-DT ≥3 months. 
Overall median PSA-
DT was significantly 
prolonged with 2.8 
months. 
The obtained median 
clinical progression-
free survival was 12.4 
weeks. 
Grade 3 toxicities of 
fatigue and 
neutropenia were 
observed. 
[274] 
5-Azacytidine 
and Valproic 
Acid 
I Completed 
5-Azacytidine was 
administered subcutaneously 
daily for 10 days in patients 
with advanced cancers (n=55), 
in which two of them with PCa. 
Cycles were 28 days ong and 
5-azacytidine was 
administered at 75 mg/m2. 
One of the two treated 
PCa patients achieved 
a 6 months’ stable 
disease. 
Data not available for 
decrease in 
methylation, neither 
for histone acetylation. 
[58] 
5-Azacytidine 
and 
Phenylbutyrate 
II 
(NCT00006019) 
 
Completed 
Patients (n=20) received 5-
azacytidine on days 1 to 7 and 
phenylbutyrate IV over 1-2 
hours on days 8 to 12. 
Additional courses in these 
patients were repeated every 
21 to 28 days in the absence 
of disease progression or 
unacceptable toxicity. 
Data not available. [278] 
5-Aza-2’-
deoxycytidine 
 
 
II 
 
Completed 
Patients with metastatic 
recurrent PCa after total 
androgen blockade and 
flutamide withdrawal (n=14) 
received an infusion of 3 
doses of 5-aza-2'-
deoxycytidine 75 mg/m2. 
Cycles of therapy were 
repeated every 5 to 8 weeks to 
allow for resolution of toxicity. 
 
Two of 12 patients 
evaluable for response 
had stable disease 
with a time to 
progression of > 10 
weeks. 
5-Aza-2'-deoxycytidine 
was well tolerated with 
modest clinical activity 
against CRPC. 
[275] 
Curcumin and 
Radiotherapy 
Study phase not 
provided 
(NCT01917890) 
Completed 
PCa patients (n=40) treated 
with external beam 
radiotherapy were separated 
in two groups 20 of them 
received 3g/day curcumin 
orally and 20 received 
placebo. 
Patients treated with 
curcumin presented 
reduced urinary 
symptoms, showing 
possible 
radioprotective effects. 
[276] 
Disulfiram 
I 
(NCT01118741) 
 
Completed 
Eligible patients (n=19) were 
≥18 years old, previously 
treated with local therapy and 
subsequently developed 
biochemically recurrent 
disease. 
Cohort 1 (n=9) and 2 (n=10) 
received disulfiram treatment 
250 mg and 500 mg daily, 
respectively. The primary 
endpoint was the proportion of 
subjects with a demethylation 
response. Secondary 
endpoints included rate of 
PSA progression at 6 months, 
changes in PSA doubling time 
and safety/tolerability. 
Only five of the 
evaluable subjects 
were on trial for ≥ 6 
months from cohort 1 
and obtained a PSA 
progression by 6 
months.  Three of the 
responders displayed 
pretreatment instability 
in their 5-
methylcytosine 
content. 
Six patients 
experienced grade 3 
toxicities. 
 
[277] 
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 Testicular Cancer 
Although testicular cancer is relatively rare, it is the most common solid tumor in 
young Caucasian men among 15-35 years old [215]. Testicular germ cell tumors (TGCTs) 
represent more than 95% of all testicular cancers and are thought to derive from primordial 
germ cells or early gonocytes [279, 280]. They are classified in two distinctive major 
histological subtypes: seminomas (40%) and non-seminomas (60%), which share the same 
precursor lesion, testicular intraepithelial neoplasia [281]. TGCTs patients are treated with 
orchiectomy with subsequent radiotherapy and chemotherapy, depending on the histology 
and clinical stage of the tumor [281]. Even metastatic patients can often be successfully 
treated with cisplatin-based chemotherapy, presenting a 5-year survival rate greater than 
70% [282]. However, 15-20% of the patients are refractory to this treatment and about 15% 
present a later relapse and develop progressive disease [283-285]. Unfortunately, there are 
no effective therapies for these patients. Seminomas are largely unmethylated, while 
nonseminomas have a global methylation status that differ according to their degree of 
differentiation [286, 287]. Nonseminomas present undifferentiated and pluripotent cells, 
known as embryonal carcinoma (EC) cells that are proposed to be TGCTs stem cells and 
the malignant homologous of embryonic stem cells [279, 280, 288]. Several methylated 
genes have been implicated in TGCTs pathogenesis, including APC, ARF, BRCA1, CALCA, 
CCNA1, HOXA9, MGMT, hMLH1, PRSS21, RARβ2, RASSF1A, SCGB3A and TP53 [289-
292]. Conversely, it was recently shown that LINE1 is extremely hypomethylated in both 
TGCTs subtypes [293]. Moreover, hypomethylation of the 5´-end of XIST gene, irrespective 
of gene expression, was described in plasma DNA of TGCTs patients [294]. A recent report 
described that an elevated methylation frequency of CALCA and MGMT was present in 
nonseminomas and was related with poor clinical outcome in TGCTs patients. In addition, 
CALCA hypermethylation was associated with refractory disease [295]. 
 
4.1.  Pre-clinical Studies 
Exposure of human EC cells to low nanomolar concentrations of 5-aza-2’-
deoxycitidine resulted in a significant decrease of cell proliferation and survival. This 
phenotype was associated with ATM pathway activation, H2AX phosphorylation, p21 
increased expression and induction of genes known to be methylated in TGCTs like MGMT, 
RASSF1A and HOXA9. Notably, not only cisplatin-resistant EC cells retain sensitivity to low 
concentrations of 5-aza-2'-deoxycytidine but also pretreatment with this agent re-sensitizes 
these cells to cisplatin-mediated toxicity. Moreover, knockdown of DNMT3B in EC cells 
reduced cell sensitivity to 5-aza-2'-deoxycytidine, supporting the role of DNMT3B in 5-aza-
2'-deoxycytidine treatment response [296]. 5-aza-2'-deoxycytidine was able to induce 
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apoptosis of human teratocarcinoma stem cells, but not in differentiated cells derived from 
human nullipotent EC cells. Intriguingly, expression of DNMT3B was required for induction 
of apoptosis and differentiation of human teratocarcinoma stem cells by 5-aza-2'-
deoxycytidine [297]. Exposure of NT2/D1 cells to low concentrations of 5-aza-2’-
deoxycitidine resulted in DNA damage, induction of p53 and global and gene specific 
promoter DNA demethylation (RIN1, SOX15, GPER and TLR4). Additionally, this treatment 
also led to downregulation of genes associated with pluripotency, like NANOG, SOX2, 
GDF3 and Myc target genes [298]. A recent study with TCam-2 seminoma cell line disclosed 
that intrinsically high resistance to cisplatin can be decreased with a pretreatment with 5-
azacytidine. Furthermore, after demethylation, the stem cell markers NANOG and POU5F1, 
as well as VASA (the germ cell-specific marker), displayed increased expression [287]. 
Intriguingly, low concentrations of SGI-110 were able to decrease tumor cell growth not only 
of cisplatin sensitive EC cells NT2/D1 and cisplatin resistant NT2/D1-R1 but also in a 
xenograft model of cisplatin resistant TGCT. Importantly, this compound re-sensitized 
refractory EC cells to cisplatin both in vitro and in vivo. The expression of GDF15, CDKN1A 
and GADD45A (p53 target genes), RASSF1 and SOX15 was induced after SGI-110 
exposure. In xenograft models, SGI-110 increased the expression of immune pathway 
genes [299]. 
 
4.2.  Clinical Trials 
A phase II clinical trial from 1977, which enrolled 214 patients with solid cancers 
evaluated the effect of high doses of 5-azacytidine. Of the four evaluable testicular cancer 
patients, two presented partial responses with 5-azacytidine doses from 225 mg/m2 to 150 
mg/m2 [300]. Roth and colleagues performed a phase II trial which enrolled 17 patients with 
refractory germ cell tumors to cisplatin treatment. Patients received 5-azacytidine at a 
dosage of 150 mg/m2/day at days 1 to 5 by continuous infusion every three weeks. All 
patients progressed on 5-azacytidine and grade 3 and 4 toxicities were observed being the 
most important granulocytopenia and anemia. Therefore, the authors were unable to 
describe any 5-azacytidine activity on patients with germ cell tumors [301]. A single-arm 
phase II study (NCT00404508) demonstrated that the combination of hydralazine with 
magnesium valproate before chemotherapy in refractory solid tumors, including one non-
seminomatous testicular cancer, resulted in decreased chemotherapy resistance with 
stable clinical response. Besides that, it was observed a clinical benefit concerning 
progression-free survival and OS of 5.6 months and 5.7 months, respectively [302]. 
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Table 6 - Clinical Trials of DNMT inhibitors in Testicular Cancer. 
DRUG PHASE (ID) STATUS SCHEDULE OUTCOME REF. 
5-Azacytidine 
 
II Completed 
Patients with solid tumors 
(n=214) were enrolled and four 
of them were testicular cancer 
patients. 5-azacytidine doses 
varied from 225 mg/m2 to 150 
mg/m2. 
Two of the four 
testicular cancer 
patients presented 
partial responses. 
[300] 
II Completed 
Patients (n=17) received 5-
azacytidine at a dosage of 150 
mg/m2/day at days 1 to 5 by 
continuous infusion every 
three weeks. 
It was not observed 
any 5-azacytidine 
activity. Grade 3 and 
4 toxicities were 
reported. 
[301] 
SGI-110 and 
cisplatin 
I 
(NCT02429466) Recruiting 
SGI-110 will be given 
subcutaneously, daily, 30 
mg/m2 on days 1-5 followed by 
cisplatin 100mg/m2 on day 8, 
every 4 weeks. 
Treatment will be continued for 
a maximum of 6 cycles or until 
disease progression or 
unacceptable toxicity. 
Data not available. [303] 
Hydralazine 
and 
Magnesium 
Valproate 
(before ChT) 
II 
(NCT00404508) Completed 
Patients with refractory solid 
tumors (n=15) received 
hydralazine at 182 mg for 
rapid, or 83 mg for slow, 
acetylators, and magnesium 
valproate at 40 mg/kg, 
beginning a week before 
chemotherapy. 
A decrease in 
chemotherapy 
resistance was 
observed. A clinical 
benefit was 
reported, namely 
stable clinical 
response a 5.6 
months progression-
free survival and an 
OS of 5.7 months. 
[302] 
ChT: Chemotherapy    
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Preliminary Data 
Urological tumors are a heterogeneous class of malignancies associated with 
significant morbidity and mortality worldwide. Although early stage disease can be 
effectively treated with surgery and/or chemo and radiotherapy, the available therapeutic 
options for advanced and metastatic disease are sparse and mainly not curative. Due to the 
high incidence and clinical aggressiveness of these malignant neoplasms, the development 
and investigation of new therapeutic regimens focused on disease biology is of major 
importance. Aberrant epigenetic alterations, especially DNA methylation, are a hallmark of 
these malignant tumors. However, these alterations are reversible and several efforts have 
been performed to design and test novel epigenetic compounds that would potentially 
reprogram tumor cell phenotype toward a normal state. It is widely accepted that natural 
compounds can modulate multiple cellular pathways, including epigenetic machinery, and 
therefore be used against several human diseases, as cancer. Importantly, these 
compounds are known not only to be safer than synthetic agents, but also present a wide 
availability, low toxicity, and good tolerability [104]. Despite their potential clinical utility, the 
field of natural compounds and their derivatives for urological cancer treatment needs to be 
further explored. 
Thus, the main goal of this dissertation was to evaluate the usefulness of four newly 
synthetized compounds derived from flavanones, as anti-cancer agents in urological tumors 
cell lines representative of the three most incident types (Bladder, Kidney and Prostate) 
through DNMT inhibition. 
Specifically, the preliminary goals of this study were: 
1. Assess the global DNA methylation profile of a range of urological tumors cell 
lines to select those with the highest 5-methylcytosine content; 
2. Determine the IC50 value of the four newly synthetized compounds in the 
previously selected cell lines to choose the most effective compound; 
3. Evaluate tumor cell viability after compounds’ exposure to identify the most 
responsive urological tumor cell line to further pursue the study.   
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 MATERIALS AND METHODS 
Cell Culture  
Epithelial cancer cell lines (ATCC, Lockville, MD, USA) representative of the various 
stages of each urological cancer (bladder, kidney and prostate) were selected. The 
characteristics and culture conditions are displayed in Table 7.  All cell lines were cultured 
in the recommended medium supplemented with 10% Fetal Bovine Serum (FBS) (Merck, 
Berlin, Germany) and 1% Antibiotic-Antimycotic (Anti-Anti (100x), GIBCO®, Life 
Technologies, USA) and were maintained at 37°C in a humidified atmosphere containing 
5% CO2. TrypLE™ Express (GIBCO) was used to harvest the cells for subculture. All 
urological cell lines were found to be negative for Mycoplasma spp. contamination (PCR 
Mycoplasma Detection Set, Takara Bio, Shiga, Japan). 
Table 7 - Growth recommended medium for each urological tumor cell line. Adapted from [304, 305]. 
Cancer 
Type Cell Line Cell Type 
Culture 
Properties 
Growth 
Medium Disease Expressed Genes 
B
LA
D
D
ER
 
5637 Epithelial Adherent RPMI-1640 Grade II carcinoma - 
J82 Epithelial Adherent 
Eagle's 
Minimum 
Essential 
(MEM) 
Grade III transitional cell 
carcinoma - 
T24 Epithelial Adherent 
McCoy's 5a 
Medium 
Modified 
Grade III transitional cell 
carcinoma 
PSA; HLA A1, A3, 
B18, Bw35, Cw4, 
DRw2, DRw4 
TCCSUP Epithelial  Adherent 
Eagle's 
Minimum 
Essential 
(MEM) 
Grade IV transitional cell 
carcinoma 
 
- 
SCaBER Epithelial Adherent 
Eagle's 
Minimum 
Essential 
(MEM) 
Squamous cell 
carcinoma - 
K
ID
N
EY
 
A-498 Epithelial Adherent 
Eagle's 
Minimum 
Essential 
(MEM) 
Primary clear cell 
carcinoma - 
769-P Epithelial Adherent  RPMI-1640 Primary clear cell 
adenocarcinoma - 
786-O Epithelial Adherent RPMI-1640 Primary clear cell 
adenocarcinoma 
Parathyroid 
hormone (PTH) like 
peptide 
Caki-2 Epithelial Adherent 
McCoy's 5a 
Medium 
Modified 
Primary clear cell 
carcinoma/papillary 
carcinoma 
- 
ACHN Epithelial Adherent 
Eagle's 
Minimum 
Essential 
(MEM) 
Adenocarcinoma; 
Derived from metastatic 
site: pleural effusion 
(papillary) 
- 
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Table 7 - Growth recommended medium for each urological tumor cell line (cont.) Adapted from [304, 305]. 
 
 
Drug Preparation and IC50 Value  
The four tested DNMTi compounds were designed, synthesized and kindly provided 
by Dr. Paola Arimondo’s Group (ETaC: Pharmacochemistry - Cancer Epigenetic Regulation 
Unit group, Centre Pierre Fabre Laboratories - Research & Development, Toulouse, 
France). All the compounds are derived from flavanones and were synthetized to optimize 
their biological activity and stability as inhibitors of DNMT3A enzyme (Table 8). Dimethyl 
sulfoxide (DMSO) (Sigma-Aldrich, USA) was used as drug solvent. The compounds were 
dissolved at 10 mM concentration and stored at -20°C until further use.  
Table 8 – Characteristic of Flavanones-derived compounds. 
 
Cancer 
Type Cell Line Cell Type 
Culture 
Properties 
Growth 
Medium Disease Expressed Genes 
PR
O
ST
AT
E 
LNCaP Epithelial 
Adherent, 
single cells 
and loosely 
attached 
clusters 
RPMI-1640 
Carcinoma;  
Derived from metastatic 
site: left supraclavicular 
lymph node; 
Androgen-responsive 
Human prostatic 
acid phosphatase; 
PSA 
22Rv1 Epithelial Adherent  RPMI-1640 
Carcinoma;  
Derived from a xenograft 
that was serially 
propagated in mice after 
castration-induced 
regression; 
Androgen-responsive 
PSA 
DU145 Epithelial Adherent 
Eagle's 
Minimum 
Essential 
(MEM) 
Carcinoma; 
Derived from metastatic 
site: brain; 
Castration-resistant 
- 
PC-3 Epithelial Adherent RPMI-1640 
com F-12K 
Grade IV 
adenocarcinoma;  
Derived from metastatic 
site: bone 
Castration-resistant 
HLA A1, A9 
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For IC50 values calculation, cell lines were exposed to a range of compound 
concentrations (1 nM, 10 nM, 100 nM, 1 µM, 10 µM and 100 µM) every 24 hours, during 
three consecutive days. For control purposes, cell lines were also exposed to the drug 
vehicle (DMSO). After three days of exposure, MTT assay was performed and the IC50 
values calculated using GraphPad Prism 6. 
 
Cell Viability Assay
Cell viability was evaluated using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium-bromide (MTT) assay. Cells were seeded onto 96-well plates at 5x104, 
1.25x104, 4x104, 2x104 and 1.5x104 cells per well for LNCaP, ACHN, Caki-2, T24 and 786-
O, respectively. Cells were allowed to adhere overnight and then exposed to the IC50 
concentration and one above of each compound or DMSO during three consecutive days, 
being the media renewed every 24 hours. Afterwards, cell viability was measured at day 0, 
1, 2 and 3. Briefly, 200 μL of 0.5 mg/mL MTT (Sigma-Aldrich) were added to each well and 
incubated in the dark at 37ºC and 5% CO2 for 1 hour. Formazan crystals were solubilized 
with 100 μL of DMSO. The absorbance was measured using a microplate reader (FLUOstar 
Omega, BMG Labtech, Offenburg, Germany) at a wavelength of 540 nm with background 
subtraction at 630 nm. Three biological and three experimental replicates were performed 
for each condition, and the number of viable cells was calculated with the following formula: ܱ𝐷 ݋݂ ݒ𝑖ܾ݈ܽ݁ ݈݈ܿ݁ݏ =  ܱ𝐷 ݁ݔ݌݁ݎ𝑖݉݁݊ݐ ×  ܰݑܾ݉݁ݎ ݋݂ ݈݈ܿ݁ݏ ܽݐ ݀ܽݕ Ͳܯ݁ܽ݊ ܱ𝐷 ܽݐ ݀ܽݕ Ͳ  
 
 
DNA Global Methylation Levels  
Imprint® Methylated DNA Quantification kit (Sigma-Aldrich, Germany) was used to 
quantify 5mC global content following manufacturer’s recommendations. Briefly, after DNA 
extraction, using the standard phenol-chloroform method (Appendix I), 200 ng of total DNA 
was incubated in the provided 8 wells strips that contain a specific solution to allow DNA 
binding and adherence to the sample well. The samples were then incubated with a 5-
methylcytosine capture and detection antibody. Absorbance was measured using FLUOstar 
Omega microplate reader at 450 nm. DNA methylation level was compared with a synthetic 
fully methylated DNA positive control. Three biological and three experimental replicates 
were performed. The determination of the percentage of global DNA methylation was 
performed using the following formula: % 𝐺݈݋ܾ݈ܽ 𝐷ܰܣ ݉݁ݐℎݕ݈ܽݐ𝑖݋݊ =  ሺ𝑀௘𝑎௡ 𝑂஽ 𝑆𝑎௠௣௟௘−𝑀௘𝑎௡ 𝑂஽ ஻௟𝑎௡௞ሻ  ሺ𝑀௘𝑎௡ 𝑂஽ 𝑀௘𝑡ℎ𝑦௟𝑎𝑡௘ௗ ஼௢௡𝑡𝑟௢௟−𝑀௘𝑎௡ 𝑂஽ ஻௟𝑎௡௞ሻ ݔ ͳͲͲ 
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 RESULTS 
Selection of the urological tumors cell lines with the highest 5mC levels 
The global DNA methylation content was determined in five BlCa cell lines (5637, 
J82, T24, TCCSUP and SCaBER), five RCC cell lines (A498, 769-P, 786-O, Caki-2 and 
ACHN) and four PCa cell lines (LNCaP, 22Rv1, DU145 and PC-3). Considering each model 
separately, T24, ACHN and LNCaP depicted the highest 5mC content (Table 9). 
Table 9 - Quantification of global DNA methylation levels for each urological tumor cell line. 
Tumor Type Samples Global DNA Methylation Levels (%) Mean 
Bladder 
Cancer 
5637 (1) 18,71559633 
19,02140673 5637 (2) 14,67889908 
5637 (3) 23,66972477 
J82 (1) 15,77981651 
16,69724771 J82 (2) 16,51376147 
J82 (3) 17,79816514 
T24 (1) 43,30275229 
34,98470948 T24 (2) 31,00917431 
T24 (3) 30,64220183 
TCCSUP (1) 46,05504587 
27,03363914 TCCSUP (2) 14,86238532 
TCCSUP (3) 20,18348624 
SCaBER (1) 14,67889908 
14,9235474 SCaBER (2) 14,31192661 
SCaBER (3) 15,77981651 
Kidney 
Cancer 
A498 (1) 10,09174312 
15,71865443 A498 (2) 18,34862385 
A498 (3) 18,71559633 
769-P (1) 15,04587156 
13,57798165 769-P (2) 12,8440367 
769-P (3) 12,8440367 
786-O (1) 14,86238532 
16,94189602 786-O (2) 9,724770642 
786-O (3) 26,23853211 
Caki2 (1) 18,34862385 
22,93577982 Caki2 (2) 28,99082569 
Caki2 (3) 21,46788991 
ACHN (1) 24,7706422 
25,19877676 ACHN (2) 17,6146789 
ACHN (3) 33,21100917 
Prostate 
Cancer 
LNCaP (1) 28,25688073 
22,62996942 LNCaP (2) 21,46788991 
LNCaP (3) 18,16513761 
22Rv1 (1) 17,79816514 
18,22629969 22Rv1 (2) 14,31192661 
22Rv1 (3) 22,56880734 
DU145 (1) 22,3853211 
21,71253823 DU145 (2) 22,75229358 
DU145 (3) 20 
PC-3 (1) 15,77981651 
17,12538226 PC-3 (2) 18,16513761 
PC-3 (3) 17,43119266 
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Calculation of the IC50 Value 
The half maximal inhibitory concentration (IC50) value of the four newly synthetized 
DNMT3A inhibitors, was calculated for each selected cell line after 72 hours of exposure 
(Table 10). The dose-response curves are represented in Appendix II. Overall, ACHN 
exhibited the lowest IC50 values for the tested compounds. Moreover, MLo-1302 was the 
compound with the lowest IC50 mean value (approximately 1.5 µM), while MLo-1507 
presented the highest IC50 mean value (approximately 14 µM). Surprisingly, this 
compound, did not demonstrate any DNMT3A inhibitory activity and therefore was included 
as a negative control (Table 8). Considering the results obtained at this stage, compound 
MLo-1302 was chosen for in vitro experiments. 
 
Table 10 – IC50 values obtained for each tested compound and for each selected 
cell line. 
 
 
Validation of MLo-1302 growth inhibitory effect  
To assess the MLo-1302 effect on tumor cell viability, the three selected cell lines 
were exposed to two different concentrations of this compound (1.5 and 3 µM) as well as to 
the vehicle (DMSO) during three consecutive days. Exposure to MLo-1302 markedly 
reduced cell viability of all tested cell lines, being the 3 µM concentration the most effective 
one (Figure 6). Whilst for T24 and LNCaP the decrease in cell viability was mainly achieved 
at the end of day 3 and with the highest tested concentration, ACHN suffered a greater 
reduction in the number of viable cells starting at day 1 and when exposed to either 1.5 µM 
or 3 µM concentrations. Considering these preliminary results, kidney cancer cell lines were 
chosen to further test the demethylation activity and the anti-cancer effects of these newly 
synthetized compounds. Despite MLo-1302 had been established as a negative control, its 
cell viability inhibitory effect and its low IC50 value, compared to the other three compounds, 
rendered it as an interesting compound to be investigated.  
13.72 µM 1.43 µM 
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Figure 6 - T24, ACHN and LNCaP cell viability after exposure to MLo-1302 and drug vehicle, at days 0, 1, 2, 
and 3, measured by MTT assay. Statistically significant differences were observed between (a) vehicle and 1.5 
µM MLo-1302, and (b) vehicle and 3 µM MLo-1302. All data are presented as mean of three independent 
experiments ± s.d. 
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Specific Aims 
Considering the preliminary results, the major goal of this Master Dissertation was 
re-defined to evaluate the demethylating and anti-neoplastic properties of these newly 
synthetized flavanones-derived compounds in RCC cell lines. 
The specific goals of this dissertation were: 
1. Calculate the IC50 value of the flavanones-derived compounds in RCC cell lines to 
choose the two most effective concentrations; 
2. Evaluate the phenotypic impact of these compounds on RCC cell lines; 
3. Investigate the influence of these compounds on DNMTs and TETs expression; 
4. Assess the compounds effects in global DNA methylation levels of RCC cell lines; 
5. Determine the effect of these novel DNMTi on DNA demethylation along with the re-
expression of genes known to be epigenetically silenced in renal cancer; 
6. Study the role of MLo-1302 in DNMT3A activity. 
 
   
     
III. MATERIALS AND 
METHODS 
   
  
 
  
| MATERIALS AND METHODS  
45 
Cell culture, drug preparation, IC50 value calculation, cell viability assay and 
quantification of global DNA methylation levels were performed as described in the previous 
section. 
 
Apoptosis Assay 
Apoptosis was assessed using the APOPercentageTM apoptosis assay kit (Biocolor 
Ltd., Belfast, Northern Ireland), according to the manufacturer’s guidelines. This assay is 
based on the movement of the transmembrane protein phosphatidylserine from the inside 
to the outside of the cell membrane layer, which results in the uptake of the APOPercentage 
dye by the apoptotic cells. Briefly, 5x104 cells/well were seeded onto 24-well plates, allowed 
to adhere overnight and treated as mentioned above. After 72 hours of compound exposure, 
5% of the APOPercentage dye was added to the media and incubated at 37ºC during 15 to 
30 minutes (depending on cell type). After PBS washing, 50 μL TrypLE™ Express was 
added to each well to allow cellular dissociation. Subsequently, 200 μL of Dye Releasing 
Agent were added and the plates were subjected to 15 minutes of intense shaking to release 
intracellular accumulated dye. The absorbance was determined using a microplate reader 
(FLUOstar Omega) at a wavelength of 550 nm with background subtraction at 620 nm. 
Three biological and three experimental replicates were performed for each condition. 
Apoptosis levels were calculated according to the following formula: ܣ݌݋݌ݐ݋ݏ𝑖ݏ ܮ݁ݒ݈݁ݏ =  ܣ݌݋ݐ݋ݏ𝑖ݏ ܱ𝐷  ܯ݁ܽ݊ ܯܶܶ ܱ𝐷 ܽݐ ݀ܽݕ 3 
The results were expressed as the OD ratio of the cells exposed to the DNMTi 
normalized to vehicle. 
 
Comet Assay  
After drug exposure, 50,000 cells were harvested by trypsinization, washed in PBS 
and re-suspended in 75 μL of low-melting point agarose (Life Technologies). This cell 
suspension was applied on top of a microscope slide containing normal-melting point 
agarose and allowed to polymerize 20 minutes at 4ºC. The slides were then, immersed in 
lysis solution, pH 10 (2.5 M NaCl, 100 mM Na2EDTA, 10 mM Tris Base and Triton X-100 
1%) at 4°C during 2 hours in the dark. Then, the slides were incubated in an alkaline 
electrophoresis buffer (300 mM NaOH, 1 mM Na2EDTA, pH 13) for 40 minutes at 4ºC to 
allow DNA unwinding. Single cell gel electrophoresis was performed on a horizontal 
electrophoresis platform at 4ºC for 30 minutes at 27V. Next, slides were immersed in 
neutralization buffer (Tris–HCl; pH-7.5, 0.4 M Tris Base) for 10 minutes. After fixation with 
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100% ethanol, the slides were stained with Sybr Green® (Life Technologies) and DNA 
damage was evaluated under a fluorescent microscope. At least three independent and two 
experimental replicates were performed for each condition. The DNA damaging effect 
through DNA fragmentation was determined by measuring four parameters previously 
described including, total intensity (DNA content), tail length, tail moment (a measure of 
both amount of DNA in the tail and its distribution) and percentage of DNA in the tail [306]. 
A minimum of 50 cells were considered for each replicate. 
 
Morphometric Analysis 
Cell morphometric analysis was performed after 3 days of compound exposure. A 
camera incorporated into Olympus phase-contrast microscope was used to capture cell 
images. Cell sphericity and area were evaluated using the freehand polygon tool of the 
Olympus cellSens Dimension software (Olympus Corporation, Shinjuku, Japan). For each 
condition, at least 50 cells from every biological replicates were analyzed. 
 
Quantitative Methylation-Specific PCR (qMSP) 
After extraction and quantification (Appendix I), 1 μg of genomic DNA was submitted 
to sodium bisulfite modification by EZ DNA Methylation-Gold™ Kit (Zymo Research, CA, 
USA) according to the manufacturer’s instructions (Appendix III). Modified DNA was eluted 
with 60 μL of sterile distilled water and stored at -80°C until further use. One μg of 
CpGenome™ Universal Methylated DNA (Millipore, USA) was also modified and eluted in 
20 μL of sterile distilled water to generate a standard curve. Bisulfite modified DNA was 
amplified by qMSP using TaqMan technology. Specific primers and a TaqMan probe for 
RASSF1A gene were designed using the Methyl Primer Express Software v1.0 (Applied 
Biosystems, Foster City, CA, USA). β-Actin (ACTB) was used as a reference gene to 
normalize for DNA input. Reactions were performed in 96-well plates using Applied 
Biosystems® 7500 Real-Time PCR System (Thermo Fisher Scientific, USA). Briefly, per 
each well 1 μL of modified DNA, 9 μL of Master Mix using AmpliTaq Gold™ (Applied 
Biosystems) were added. The primers and probes volumes used for each gene as well as 
their sequences are listed in Table 11. The amplification was carried out by a period of 10 
minutes at 95°C followed by 45 cycles with 15 seconds at 95°C and 1 minute at specific 
temperature (Table 11). All the samples were run in triplicates. The methylation levels for 
each sample were derived from calibration curves created using serial dilutions (1:5) of 
bisulfite modified CpGenomeTM Universal Methylated DNA. The methylation levels for each 
gene were calculated after normalization to ACTB. 
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Table 11 - Primers and Probes sequences and qMSP conditions for each studied gene. 
Gene Primers Sequences (5’ → 3’) Volume 
(µL) F+R* 
Annealing 
Temperature (°C) 
ACTB 
F: TGG TGA TGG AGG AGG TTT AGT AAG T  
0.4 
60 
R: ACC AAT AAA ACC TAC TCC TCC CTT AA  
Probe: FAM- ACC ACC ACC CAA CAC ACA ATA ACA AAC 
ACA -TAMRA  0.02 
RASSF1A 
F: GCG TTG AAG TCG GGG TTC G 
0.6 
62 R: CCC GTA CTT CGC TAA CTT TAA ACG  
Probe: FAM- ACA AAC GCG AAC CGA ACG AAA CCA -
TAMRA  
0.02 
*
 Primers Forward (F) plus Reverse (R) at a concentration of 10 µM. 
 
Quantitative Reverse Transcription PCR (qRT-PCR) 
After compound exposure, RNA was extracted from cell lines using TRIzol® (Life 
Technologies) following manufacturer’s instructions (Appendix IV). Complementary DNA 
(cDNA) synthesis was performed using the RevertAid Reverse Transcription Kit (Thermo 
Scientific, MA, USA) (Appendix V). Expression of target genes was quantified using 
NZYSpeedy qPCR Green Master Mix (2x), ROX (NZYTech) for GUSB, DNMT1, DNNMT3a, 
DNMT3b, RASSF1A, TET1, TET2 and TET3. Expression of CASP3, CDKN1A, GUSB and 
KI67 was quantified using Taqman expression assays (purchased as pre-developed assays 
from Applied Biosystems) and NZYSpeedy qPCR Probe Master Mix (2x), ROX (NZYTech). 
The expression of each target gene was then normalized to the expression of the 
housekeeping gene (GUSB). Primers and PCR conditions used for each target gene are 
displayed in Table 12. The PCR program was performed using Applied Biosystems® 7500 
Real-Time PCR System (Thermo Fisher Scientific) and all the samples were run in triplicate. 
Human Reference Total RNA (Agilent Technologies, USA) was used as positive control to 
generate a standard curve (dilutions of 1:10).   
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Table 12 - Primers sequences and qRT-PCR conditions for each target gene. 
Gene Primers Sequences (5’ → 3’) / Assay Reference Volume 
(µL) F+R* 
Annealing 
Temperature (°C) 
CASP3 Hs00234387_m1 0.5 60 
CDKN1A Hs00355782_m1 0.5 60 
DNMT1 
F: TAT CCG AGG AGG GCT ACC TG  
0.5 60 
R: ATG AGC ACC GTT CTC CAA GG   
DNMT3a 
F: TAT TGA TGA GCG CAC AAG A 
0.5 60 
R: GGG TGT TCC AGG GTA ACA TTG AG 
DNMT3b 
F: GAA TTAC TCA CGC CCC AAG GA  
0.5 60 
R: ACC GTG AGA TGT CCC TCT TGT C  
GUSB 
F: CTC ATT TGG AAT TTT GCC GAT T  
0.5 
61 
R: CCG AGT GAA GAT CCC CTT T 
GUSB Hs99999908_m1 0.5 60 
Ki67 Hs01032427_m1 0.5 60 
RASSF1A 
F: AGC GCC CAA AGC CAG CGA AGC ACG G 
0.5 60 
R: CCC GCA ACA GTC CAG GCA GAC GAG C 
TET1 
F: ACC TGC AGC TGT CTT GAT CG  
0.2 62 
R: TTT CCC TGA CAG CAG CAA CA 
TET2 
F: ACG CTT GGA AGC AGG AGA T 
0.3 64 
R: AAG GCT GCC CTC TAG TTG AA 
TET3 
F: CCC ACA AGG ACC AGC ATA AC  
0.3 62 
R: CCA TCT TGT ACA GGG GGA GA 
*
 Primers Forward (F) plus Reverse (R) at a concentration of 10 µM.  
DNMT3A Activity Assay 
Nuclear extracts from either compound treated or vehicle exposed cells were 
obtained using the Nuclear Extract Kit (Active Motif, Rixensart, Belgium) as instructed in the 
manufacturer’s protocol. After protein quantification through Pierce BCA Protein Assay kit, 
(Thermo Scientific), 10 µg of nuclear extract obtained from each sample was used to 
measure DNMT3A activity with EpiQuick™ DNMT3A Assay Kit, a sensitive ELISA-based 
kit (Epigentek, New York, USA), according to the manufacturer’s instructions. Briefly, 
nuclear extracts were added to a specific 96 well plate coated with CpG enriched substrate. 
After the enzymatic reaction, capture and detection antibodies were added to the wells. 
Absorbance was measured using FLUOstar Omega microplate reader, at 450 nm with 
background subtraction at 655 nm. Three biological and three experimental replicates were 
performed for each sample. The subsequent formula was used to calculate the DNMT3A 
activity percentage: 
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% 𝐷ܰܯܶ3ܽ ܣܿݐ𝑖ݒ𝑖ݐݕ =  ሺܱ𝐷 ܶݎ݁ܽݐ݁݀ ܵܽ݉݌݈݁ − ܱ𝐷 ܤ݈ܽ݊݇ሻ  ሺܱ𝐷 𝑉݁ℎ𝑖݈ܿ݁ − ܱ𝐷 ܤ݈ܽ݊݇ሻ ݔ ͳͲͲ% 
 
Statistical Analysis 
One-way analysis of variance (ANOVA), with post-hoc Dunnet’s multiple 
comparison test was used to compare the results obtained in each parameter for the 
different compounds concentrations and the control/vehicle, when appropriated. On the 
other hand, in the absence of normality, the non-parametric Kruskal-Wallis was applied. 
Analysis was performed with GraphPad Prism 6, and statistical significance was set at p-
value < 0.05. 
   
   
  
   
          
IV. RESULTS 
   
 
   
| RESULTS  
53 
IC50 value of flavanones-derived compounds in RCC cell lines 
The IC50 value was calculated for each compound in three RCC cell lines, one 
derived from clear cell carcinoma, 786-O, and two derived from papillary carcinoma, ACHN 
(metastatic) and Caki-2 (primary) using MTT assay (Table 13). Compound MLo-1302 
exhibited the lowest IC50 mean value in the three cell lines, approximately 1.5 μM compared 
to 9.5, 11 and 8.5 μM of compounds DD880, MLo-1507 and MLo-1508, respectively (dose-
response curves in Appendix II). 
Table 13 – IC50 values obtained for each tested compound and for each selected 
cell line. 
 
 
 
 
 
 
 
 
Since the IC50 mean value of all the compounds, with exception of MLo-1302, were 
quite similar, the phenotypic impact and the inhibitory effect on DNMT expression were 
assessed for all the four compounds to further select the one with the greatest anti-cancer 
potential. Importantly, all the cell lines were exposed to the IC50 concentration and one 
above, as indicated in Table 14. 
 
Table 14 – Concentrations of the four flavanones derived compounds used for each RCC cell lines. 
  Compounds’ Concentrations 
  
DD880 MLo-1302 MLo-1507 MLo-1508 
Cell Lines 
786-O 5 µM 10 µM 1.5 µM 3 µM 15 µM 30 µM 12 µM 24 µM 
Caki-2 10 µM 20 µM 1.5 µM 3 µM 15 µM 30 µM 12 µM 24 µM 
ACHN 10 µM 20 µM 1.5 µM 3 µM 7.5 µM 15 µM 2 µM 4 µM   
 DD880 MLo-1302 MLo-1507 MLo-1508 
786-O 4.77 μM 1.45 μM 12.82 μM 12.03 μM 
Caki-2 12.59 μM 1.30 μM 12.30 μM 11.32 μM 
ACHN 10.86 μM 1.03 μM 7.20 μM 1.84 μM 
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Phenotypic effects  
 Flavanones-derived compounds attenuated RCC cells malignant 
phenotype 
A time- and dose-dependent inhibition of RCC cell viability was observed for all the 
four compounds. Overall, the tumor cell growth suppression was evident from day 1 and 
with both tested concentrations (Figure 7).   
 
Figure 7 - Impact of the four flavanones-derived compounds, (A) DD880, (B) MLo-1302, (C) MLo-1507, (D) 
MLo-1508, on cell viability of RCC cell lines, 786-O, Caki-2 and ACHN, at days 0, 1, 2, and 3, measured by MTT 
assay. Statistically significant differences were observed between (a) vehicle and IC50 mean concentration, and 
(b) vehicle and the double IC50 mean concentration. All data are presented as mean of three independent 
experiments ± s.d. 
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Corroborating the preliminary results, MLo-1302 was the most effective compound 
by consistently reducing the cell viability of the three tested RCC cell lines in the same 
proportion. Moreover, MLo-1302 was the only compound in which the IC50 value really 
reduced RCC cell viability in 50% (Table 15). Nonetheless, similar findings were observed 
for compounds DD880 and MLo-1507, being the lowest reduction of tumor cell growth 
attained with MLo-1508, particularly in ACHN cell line.  
 
Table 15 – Percentage of viable cells after 3 days of compound exposure in RCC cell lines. 
 DD880 MLo-1302 MLo-1507 MLo-1508  
 
5 10 20 1.5 3 7.5 15 30 2 4 12 24 µM 
786-O 67.9 8.5 - 52.8 17.4 - 60.1 20.1 - - 76.5 19.8 % of 
Viable 
Cells 
(day 3) 
Caki-2 - 77.1 21.1 55.7 9.5 - 53.6 16.8 - - 74.0 41.9 
ACHN - 63.9 21.2 39.5 14.5 92.3 47.1 - 84.2 84.3 - - 
 
All tested compounds induced a significant increase in apoptosis levels (Table 16). 
In accordance with the cell viability results, apoptosis induction was dose-dependent (Figure 
8).  DD880 showed the highest impact in apoptosis, especially in 786-O with 10 μM and in 
ACHN with 20 μM concentration (Figure 8A), whereas the lowest apoptotic levels were 
achieved with MLo-1508, being ACHN the less responsive cell line (Figure 8D). The 
remaining two compounds also displayed a pronounced effect in RCC cells death, being 
Caki-2 the most responsive to MLo-1302 (Figure 8B) and 786-O to MLo-1507 (Figure 8C). 
 
Table 16 - Apoptosis levels after 3 days of compound exposure (normalized to respective vehicle). 
 DD880 MLo-1302 MLo-1507 MLo-1508  
 
5 10 20 1.5 3 7.5 15 30 2 4 12 24 µM 
786-O 5.0 30.7 - 1.8 8.6 - 12.3 46.0 - - 2.7 11.1 
Apoptosis 
Levels  
(day 3) 
Caki-2 - 3.0 8.2 1.5 13.8 - 1.8 5.5 - - 2.9 6.6 
ACHN - 11.7 40.2 2.4 6.3 3.3 8.6 - 2.0 2.1 - - 
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Figure 8 - Effect of the four flavanones-derived compounds, (A) DD880, (B) MLo-1302, (C) MLo-1507, (D) MLo-
1508, in apoptosis levels of RCC cell lines, measured at day 3, with a phosphatidylserine-based assay. All data 
are presented as mean of three independent experiments ± s.d. (*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001).  
Molecular analysis of key genes associated with phenotypic features were 
performed in RCC cell lines exposed to the most effective compounds, DD880 (in 
apoptosis) and MLo-1302 (in cell viability). Indeed, the expression of two genes involved in 
cell proliferation pathway (CDKN1A and KI67) and one gene that is triggered in apoptosis 
(CASP3) were assessed. Generally, the molecular results corroborated the phenotypic 
data. A significant decrease in KI67 along with a significant increase in CDKN1A transcript 
levels was depicted for all RCC lines with DD880, especially at 10 μM concentration (Figure 
9A). Whereas, for MLo-1302 exposure, only a significant Ki67 levels’ reduction was found 
in ACHN. However, CDKN1A expression was increased after exposure to 3 µM MLo-1302 
in Caki-2 and ACHN (Figure 9B). Regarding apoptosis, a significant augment in CASP3 
mRNA levels was found after exposure to all the compounds (Figure 9). Insufficient RNA 
and DNA did not allow for molecular evaluation of ACHN cell line treated with 20 μM DD880. 
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Figure 9 – mRNA expression of KI67, CDKN1A and CASP3, normalized to GUSB, in vehicle and drug exposed 
RCC cells after three days of exposure to (A) DD880 or (B) MLo-1302 (*p<0.05; **p<0.01; ***p<0.001; 
****p<0.0001). 
 
 
 Flavanones-derived compounds led to alterations in RCC cell morphology  
Flavanones-derived compounds induced visible alterations in cell morphology of all 
RCC cell lines. Although a significant cell area increase was disclosed for 786-O and ACHN 
exposed to MLo-1302 (Figure 10B), the remaining compounds mainly caused a significant 
decrease of this parameter (Figure 10A, C and D). Moreover, an increase in cell granularity 
and nuclei heterochromatic regions were also apparent, which combined with the small 
sized cell population are common features of apoptotic cells. Interestingly, cell vacuolization 
and debris were common at the highest compound concentration (Table 17). Globally, a 
significant increase in cell sphericity was observed in treated cells when compared to drug 
vehicle, especially for MLo-1302 (Figure 11B) and MLo-1507 (Figure 11C). Illustrations of 
drug-induced morphometric alterations are shown in Appendix VI.  
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Figure 10 – Morphometric alterations induced on 786-O, Caki-2 and ACHN after exposure to the four 
flavanones-derived compounds, (A) DD880, (B) MLo-1302, (C) MLo-1507, (D) MLo-1508, considering 
variations in cell area, compared with vehicle. All data are presented as mean of three independent experiments 
± s.d. (**p<0.01; ***p<0.001; ****p<0.0001). 
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Figure 11 – Cell sphericity alterations induced in RCC cell lines after exposure to the four compounds, (A) 
DD880, (B) MLo-1302, (C) MLo-1507, (D) MLo-1508, compared with vehicle. All data are presented as 
mean of three independent experiments ± s.d. (*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001).  
Table 17 – Morphometric alterations induced by the four flavanones-derived compounds in RCC cell lines. 
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 Flavanones-derived compounds induced DNA damage in RCC cell lines 
As demonstrated by the increased comet tail length, RCC cell lines exposure to each 
one of the flavanones-derived compounds caused significant DNA damage, excepting for 
ACHN exposed to MLo-1508 (Figure 12). Furthermore, tail moment allowed quantification 
of DNA fragmentation which is calculated through multiplication of DNA percentage in the 
tail by the distance between the means of the head and tail distributions. Representative 
images were chosen to illustrate drug-induced DNA damage by MLo-1302 (Figure 13). The 
remaining images for each compound are presented in Appendix VII.  
 
Figure 12 – Effect of the four flavanones-derived compounds, (A) DD880, (B) MLo-1302, (C) MLo-1507, (D) 
MLo-1508, on DNA damage of RCC cell lines measured by mean tail moment. All data are presented as mean 
of three independent experiments ± s.d. (*p<0.05; ***p<0.001; ****p<0.0001). 
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Figure 13 – MLo-1302 effect on DNA damage. Comet assay immunofluorescence images of vehicle and 1.5 
µM and 3 µM MLo-1302 exposed cells counterstained with Syber Green. All data are presented as mean of 
three independent experiments ± s.d.  
Effects on DNA Methylation  
 Flavanones-derived compounds associated with DNMTs altered 
expression in human RCC cell lines 
A significant increase in DNMT1 expression levels were observed in cells exposed 
to DD880, MLo-1507 and MLo-1508 compounds, with exception of 786-O treated with 
DD880 (Figure 14A), where no changes were apparent. Furthermore, a significant reduction 
in DNMT3a was verified in ACHN after exposure to DD880 (Figure 14A). Overall, MLo-1302 
induced the greatest DNMTs expression inhibitory effect in the tested RCC cell lines. 
Indeed, this compound not only reduced DNMT1 expression levels in Caki-2 but also 
DNMT3a in all treated cell lines. Surprisingly, all cell lines displayed a significant increase 
of DNMT3b expression levels after MLo-1302 exposure (Figure 14B). Additionally, Caki-2 
exposure to MLo-1507 (Figure 14C) and MLo-1508 (Figure 14D) was associated with a 
significant decrease of DNMT3a expression levels. Nonetheless, 786-O and Caki-2 
exposed to DD880 and ACHN treated with MLo-1507 displayed increased DNMT3a mRNA 
levels (Figure 14A and C). Besides that, a significant reduction of DNMT3b expression was 
depicted in both Caki-2 and ACHN cell lines exposed to MLo-1508 (Figure 14D). In view of 
these results conjugated with the previous described phenotypic effects, the additional 
experiments were conducted only with DD880 and MLo-1302. 
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Figure 14 – Impact of the four flavanones-derived compounds (A) DD880, (B) MLo-1302, (C) MLo-1507, (D) 
MLo-1508, on DNMT1, DNMT3a and DNMT3b mRNA expression in the three tested RCC cell lines, normalized 
to GUSB, in vehicle and drug exposed cells. All data are presented as mean of three independent experiments 
± s.d. (*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001). 
 
 Flavanones-derived compounds associates with TETs upregulation in 
human RCC cell lines 
TETs expression was also evaluated in RCC cells exposed to the newly synthetized 
compounds. Interestingly, excepting ACHN treated with MLo-1032, both compounds 
induced TET1 expression in the tested cell lines, (Figure 15A and B). Additionally, DD880 
increased TET2 and TET3 transcript levels in Caki-2 and 786-O, respectively (Figure 15A), 
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whereas MLo-1302 significantly augmented TET2 expression in 786-O and Caki-2, and 
increased TET3 expression levels in ACHN cell line (Figure 15B). 
 
Figure 15 – Impact of (A) DD880 and (B) MLo-1302 on mRNA expression levels of TET1, TET2 and TET3 in 
RCC cell lines, normalized to GUSB, in vehicle and drug exposed cells. All data are presented as mean of three 
independent experiments ± s.d. (*p<0.05; **p<0.01; ****p<0.0001).  
 MLo-1302 decreased global DNA methylation levels in RCC cell lines 
A slight (~6.5%), though significant, decrease in global 5-mC content was observed 
in 786-O exposed to DD880 (Figure 16A). In contrast, MLo-1302 significantly reduced 
global methylation levels of all RCC cell lines, particularly at lower concentration, being the 
most significant reduction found in ACHN (70%) (Figure 16B). 
 
Figure 16 - Effect of (A) DD880 and (B) MLo-1302 on global DNA methylation of 786-O, Caki-2 and ACHN. 
Data are presented as mean of three independent experiments ± s.d. (*p<0.05; **p<0.01; ***p<0.001; 
****p<0.0001). 
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 Flavanones-derived compounds induced re-expression of genes 
epigenetically silenced in RCC 
The promoter methylation and expression levels of RASSF1A, a gene known to be 
regulated by hypermethylation in RCC, were evaluated. Although exposure to DD880 
resulted in an unexpectedly increase of RASSF1A methylation levels in 786-O and ACHN 
(Figure 17A), significant increased expression levels were observed in all RCC cell lines 
treated with 10 µM DD880 (Figure 17A). Regarding MLo-1302, a significant RASSF1A 
promoter demethylation and concomitant re-expression was depicted in ACHN cell line 
exposed to 3 µM concentration (Figure 17B).  
 
Figure 17 – Effect of (A) DD880 and (B) MLo-1302 exposure on RASSF1A methylation and expression levels, 
normalized to ACTB and GUSB, respectively, in vehicle and drug exposed cells. All data are represented as 
mean of three independent experiments ± s.d. (*p<0.05; **p<0.01; ****p<0.0001). 
 
 MLo-1302 induced alterations in DNMT3A activity in human RCC cell lines 
Due to the surprisingly decrease in DNMT3a expression and in the global DNA 5-
methylcytosine content induced by MLo-1302, the activity of this enzyme was also 
evaluated in RCC cells. Interestingly, a statistically significant 56% reduction of DNMT3A 
activity was found in Caki-2 exposed to 3 µM MLo-1302 (Figure 18). Conversely, a 24% 
significant increase was observed for 786-O cell line treated with 1.5 µM MLo-1302 (Figure 
18). Although without reaching statistical significance a 40% decrease in DNMT3A activity 
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was depicted by ACHN exposed to both concentrations (p=0.075 for 1.5 µM MLo-1302 and 
p=0.066 for 3 µM MLo-1302) (Figure 18).  
 
    
 
 
Figure 18 – Effects of MLo-1302 exposure on DNMT3A activity of RCC cell lines compared with vehicle. Data 
are presented as mean of three independent experiments ± s.d. (*p<0.05; **p<0.01). 
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Discussion 
Cancers of the bladder, kidney and prostate rank among the ten most common 
malignancies worldwide, affecting mainly middle-age individuals. Currently, due to the 
important morbidity, they represent a heavy economic burden on the healthcare system. 
Moreover, among all genitourinary tumors, RCC is the most lethal [307, 308]. Despite the 
use of modern imaging methods that allow early detection of localized RCC, enabling 
curative therapeutic options, about 25-30% of the patients progressively develop metastasis 
and die [309, 310]. Moreover, about one third of RCC patients are already diagnosed with 
metastatic disease. At this disease stage, therapy regimen with TKIs allows for disease 
control, increasing survival for up to 9 months. This treatment, however, is not curative and 
eventually all metastatic RCC (mRCC) patients will develop TKI-resistance, facing an 
extremely poor prognosis, with a 5-year survival rate inferior to 10% [162, 163]. Therefore, 
the development of novel and more effective drugs for treatment of advanced disease is 
mandatory. 
Deregulation of epigenetic machinery has been implicated in renal carcinogenesis. 
Until now, many efforts have been done to identify target genes dysregulated through 
epigenetic mechanisms [311]. Importantly, several TSGs involved in pathways that 
contribute to cellular homeostasis maintenance were found silenced by promoter 
methylation in RCC [177, 311]. In fact, TSGs hypermethylation has been reported in about 
20% and 7% of ccRCC and pRCC, respectively [312, 313]. Moreover, these carcinomas 
also present a CpG island methylator phenotype (CIMP) which confer a more aggressive 
behavior, specifically in pRCCs which was associated with worse overall survival [313, 314]. 
DNMT1, 3A and 3B proteins were also found overexpressed in the three most frequent 
sporadic RCC subtypes being associated with poor prognosis [315]. Therefore, DNMT 
inhibitors might be a useful therapeutic tool for RCC. Indeed, the two FDA-approved 
nucleoside DNMTi (although for hematological neoplasia) have already been used in RCC 
clinical trials as monotherapy or in combination with other therapeutic agents [208-210]. 
However, compared with hematological malignancies, 5-azanucleosides showed reduced 
effectiveness in RCC, similarly to other solid tumors. This might be due to limited 
incorporation into DNA, since RCC cells are much less proliferative when compared to 
hematological neoplasms [316]. Thus, non-nucleoside DNMTi, which do not need to be 
incorporated into DNA, might overcome this limitation. Remarkably, most of DNMTi 
compounds were intended to target DNMT1, whereas DNMT3A and 3B inhibition has been 
less explored. Although DNMT1 is the most important DNMT enzyme due to its role in DNA 
methylation marks maintenance, DNMT3A and 3B, once responsible for de novo 
methylation, should also be considered. 
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In this study, we report for the first time, the anti-neoplastic activity of four newly 
synthetized flavanones-derived compounds in RCC cell lines. Interestingly, these 
compounds reduced cell viability and induced cell death through apoptosis in a dose- and 
time-dependent manner, being the most effective response achieved with the highest 
concentration for all the compounds. Overall, the phenotypic assays revealed that DD880 
and MLo-1302 were the most effective compounds. Remarkably, a 91.5% reduction of cell 
viability in 786-O cell line after 72h exposure to 10 µM DD880 was observed. This result 
surpasses the 23.6% inhibition obtained with 20 µM EGCG, another polyphenol compound, 
after 6 days of treatment [317]. Moreover, in a recent study, exposure of 786-O cells to 100 
µg/ml EGCG during 48h resulted in a 30-35% reduction of cell viability [318], corresponding 
to a 10-fold higher concentration than the highest used in our study. In fact, 30 µM MLo-
1507 decreased 786-O growth in about 64% within the same exposure time. Comparing to 
5-aza-2’-deoxycytidine, which reduced Caki-2 cell viability in approximately 53% and 
augmented apoptosis 4.38-fold after 96h of treatment with 5 µM concentration [178], 3 µM 
MLo-1302 decreased Caki-2 cell viability and increased apoptosis in a more expressive 
manner (90.5% and 13.8-fold, respectively), suggesting that MLo-1302 might be a more 
effective anti-neoplastic compound. Importantly, both reduction of cell viability and 
apoptosis increase were confirmed at the molecular level through an overall significant 
decrease of KI67 transcript levels, a well-known cell proliferation marker, and increased 
CDKN1A gene expression, after exposure to either DD880 or MLo-1302 compounds. 
Moreover, significantly augmented CASP3 mRNA expression also corroborates the results 
obtained with apoptosis assay, for both compounds. 
All the four tested flavanones-derived compounds induced alterations in cell 
morphology of the three RCC cell lines tested. The increased cell sphericity depicted after 
compound exposure is, indeed, a marker of the acquisition of a more epithelial phenotype 
indicating attenuation of aggressiveness. This is in accordance with the previous phenotypic 
results regarding cell viability impairment and apoptosis induction. Interestingly, MLo-1302 
induced a dose-dependent increase in 786-O and ACHN cell area. This might be due to cell 
swelling, suggesting cell death due to necrosis. However, since cell area increment was 
followed by increased heterochromatic foci, it might also be indicative of cellular 
senescence. Therefore, the mechanism of death in these two cell lines requires further 
elucidation. Conversely, the remaining compounds disclosed a significant reduction in cell 
area in all tested cell lines, which along with increased heterochromatic regions and cellular 
fragmentation, are suggestive of the apoptotic effect, supporting the results obtained with 
the APOPercentageTM assay. Furthermore, and except for MLo-1508 in ACHN, marked 
DNA damage was also depicted after exposure to the tested compounds in both 
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concentrations. These results might be of particularly importance, since DNA repair has 
been implicated in therapy-resistance [319]. Therefore, DNA repair machinery impairment 
induced by these compounds might be beneficial for standard cancer therapy. Moreover, 
DNA damage-induced phenotype might render RCC cells sensitive to poly(ADP-ribose) 
polymerase (PARP) inhibitors [320], and thus, these compounds might also be useful as 
chemosensitizers.  
Interestingly, lower MLo-1302 concentration (1.5 µM) decreased global DNA 
methylation content in all tested RCC cell lines. In fact, a 70% reduction was achieved in 
ACHN and 55-60% for the remaining cell lines. This results are in line with the 50% global 
5-methylcytosine content reduction observed in Caki-2 cell line treated with 1 µM 5-aza-
deoxycytidine reported elsewhere [183]. Interestingly, MLo-1302 was also the flavanones-
derived compound that presented the greatest DNMTs expression inhibitory effect, with 
significant DNMT1 expression reduction in Caki-2, and DNMT3a downregulation in all RCC 
cell lines. Intriguingly, this compound also led to 56% decrease in DNMT3A activity in Caki-
2 cell line. Nonetheless, because MLo-1302 was synthesized to be a negative control for 
DNMT3A inhibition, these results are somewhat unexpected. Indeed, it is noteworthy that 
this compound has a IC50 value similar to 5-aza-2’-deoxycytidine and displayed a higher 
phenotypic impact in RCC cell lines. It is widely known that natural compounds (including 
curcumin, ECGC, genistein and PEITC) downregulate DNMTs expression in several cancer 
models, including prostate, colon, esophageal and breast cancer [104, 106, 118, 265, 321]. 
However, they are weak DNMTs inhibitors in RCC cell lines. In fact, in ACHN cell line, 50 
µM genistein only reduced DNMT3B expression in about 27%, whereas no significant effect 
was observed for DNMT1 and DNMT3A [119]. Thus, the hypothesis that MLo-1302 is a new 
anti-neoplastic compound with impact on DNA methylation should be considered and 
further explored. Concerning the other three compounds, DD880 reduced DNMT3a 
transcript levels in ACHN, while MLo-1507 and MLo-1508 decreased DNMT3a expression 
in Caki-2. No significant inhibition of DNMTs expression was detected in 786-O cells. These 
results might be related to the fact that ACHN and Caki-2 (both pRCC), exhibit higher global 
DNA methylation than 786-O, a ccRCC cell line.  
Furthermore, increased TETs mRNA expression levels, suggestive of an active 
demethylating mechanism, was observed in all RCC cell lines treated with DD880 and MLo-
1302. After exposure to both compounds, the highest expression levels were observed for 
TET1. Importantly, this enzyme was previously reported to be downregulated in RCC, 
correlating with poor prognosis. Similarly, in ACHN cells, TET1 ectopic overexpression 
significantly associated with decreased cell viability and invasion, as well as increased 
apoptosis [322]. Overall, these data suggest that phenotypic effect of these two novel 
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compounds may result, at the least partially, from induced TET1 re-expression. Thus, 
RASSF1A re-expression might result from the combined increased TETs expression and 
reduced DNMTs expression and activity. RASSF1A silencing by promoter methylation is 
present in about 30-100% of RCC [172, 323]. Demethylation and respective re-expression 
(6-fold) was only achieved in ACHN treated with 3 µM MLo-1302. Conversely, exposure to 
the highest concentration of DD880 was associated with increased RASSF1A methylation 
levels in both 786-O and ACHN, whereas RASSF1A re-expression was observed in all 
DD880 treated RCC cells.  
It should be recalled that epigenetic regulation comprise several interconnected and 
complex mechanisms, including histone post-translational modifications [10]. Indeed, 
natural compounds such as ECGC, genistein and curcumin also modulate HDACs and 
induce histone acetylation in other cancer models [324-327]. In RCC, exposure of ACHN 
cells to 50 µM genistein incremented histone acetylation along with repressive marks 
inhibition [119]. Additionally, most of the natural compounds exhibit stereogenic centers and 
fused ring systems which render them as higher complex molecules that simultaneously act 
in several targets. Their ability to interact with several protein families, like DNMTs, HDACs, 
HATs, hinder the precise characterization of its anti-neoplastic effects, being difficult to 
distinguish whether their effects result from direct modulation of one or more epigenetic 
targets [328]. This might explain the observed RASSF1A re-expression without significant 
promoter demethylation. Therefore, the interaction of these drugs with other epigenetic 
enzymes, such as histone acetylases and deacetylases should not be excluded and must 
be further investigated. Conversely, RASSF1A re-expression through promoter 
demethylation in ACHN cell line treated with MLo-1302 represents a pivotal result 
concerning the mode of action of this compound. In fact, similar results were achieved with 
200 nM 5-aza-2’-deoxycytidine after 2-6 days of treatment of the same line [329]. Likewise,  
786-O cells exposure to 5 µM 5-aza-2’-deoxycytidine reduced RASSF1A promoter 
methylation and a 50 to 100-fold re-expression was achieved [185].  
Nonetheless, since MLo-1302 does not need to be incorporated into DNA molecule 
and was demonstrated to attenuate malignant features in RCC at low concentrations, it 
might be useful in clinical practice. Importantly, when compared to synthetic agents, natural 
compounds, which are present in the regular diet, have been considered safer and more 
advantageous regarding their tolerability and availability [104]. Although epidemiological 
studies have shown a correlation between increased antioxidants intake and lower tumor 
morbidity and mortality rates [330, 331], there is no data available regarding the anti-
neoplastic activity of flavanones family in kidney cancer [116]. Thus, our study might well 
represent the first approach to this important issue.  
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Conclusions 
Herein, we demonstrated that the four newly synthesized flavanones-derived 
compounds attenuated RCC malignant phenotype. Moreover, MLo-1302 was the most 
effective compound in tumor growth inhibition. Importantly, this agent was not only able to 
efficiently induce phenotypic alterations in RCC cells, but also significantly decreased DNA 
methylation at both global and loci specific levels. Further studies are now mandatory to 
disclose its role as a novel anti-neoplastic DNMTi for RCC therapy. 
 
Future Perspectives  
In this work, we have investigated four newly synthesized flavanone-derived 
compounds as potential anti-neoplastic agents. Although their tumor-growth inhibitory effect 
was proven, there is much to be unveiled about their mechanism of action. Indeed, the 
expression of genes, both at transcript and protein levels, representative of the cancer 
hallmarks, need to be evaluated to further validate the previous results and to explore their 
therapeutic potential for RCC management.  
Additionally, since phenotypic data suggested an effect in cellular senescence and 
DNA repair, the assessment of key players of these mechanisms, such as Laminin, E-
cadherin and PARP1, might also be investigated. 
To validate the demethylation activity of these compounds, we plan to evaluate the 
methylation and expression levels of additional epigenetically regulated genes implicated in 
renal carcinogenesis. It would also be interesting to understand the apparently contradictory 
results obtained for RASSF1A, assessing the effect of these compounds in chromatin 
remodeling, namely by studying HDACs deregulation as well as alterations in histone 
acetylation (e.g. H3ac and H4ac).  
Finally, the activity levels of DNMT1 and 3B and proteins levels of the three DNMTs 
implicated in CpG methylation should also be evaluated in RCC cells exposed to the 
flavanone-derived compounds to accurately identify their targets. 
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APPENDIX I – DNA Extraction: Phenol-Chloroform Method 
The cell lines’ pellet was centrifuged at 13 000 rpm for 5 minutes. Then, the samples 
were digested in 500 µL of SE solution (75 mM NaCl and 25 mM EDTA), 30 µL of 10% SDS 
(Sigma-Aldrich, Germany) and 15 μL of proteinase K (20 mg/mL) (NZYTech, Portugal) by 
incubation overnight in a bath at 55°C, by adding proteinase K (20 mg/mL) every 12h until 
completed digestion.  
 DNA extraction was performed within Phase Lock Gel Light tubes (5PRIME, 
Germany) previously centrifuged at 12 000 rpm for 5 minutes, at 4°C. After that, 500 µL of 
phenol-chloroform solution at pH=8 (Sigma-Aldrich, Germany; Merck, Germany) and 
samples were added to the tubes. The mixture was centrifuged at 13 000 rpm for 15 
minutes, at 4°C, and the upper aqueous phase containing DNA was transferred to new 2 
mL tubes together with two-fold volume of absolute ethanol (Merck, Germany) and 1/3 
volume of 7.5 M Ammonium acetate (Sigma-Aldrich, Germany) of original amount of this 
phase. If necessary, 2 µL of glycogen may be added to help in DNA precipitation. 
The samples were placed overnight at -20°C to precipitate DNA. These components 
were centrifuged for 20 minutes at 13 000 rpm and at 4°C. The supernatant was discarded 
and washed twice with cold 70% ethanol. Lastly, pellets were air dried and eluted in sterile 
distilled water (B. Braun, Melsungen, Germany) with a volume that depends on pellet size.   
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APPENDIX II – Dose-response curves 
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APPENDIX III – Sodium Bisulfite Modification: EZ DNA Methylation-Gold™ Kit  
Genomic DNA extracted from cell lines was submitted to bisulfite sodium conversion 
and 1000 nanograms of DNA were used, according to DNA concentration obtained. Sterile 
distilled water was added depending on the DNA volume of each sample necessary to 
obtain 1000 nanograms, up to a total volume of 20 µL. Besides, 130 µL of CT Conversion 
reagent was also added to each sample. After centrifugation at 4 000 rpm for 30 seconds, 
the mixtures were incubated in MyCycler™ Thermal Cycler System (Bio-Rad, California, 
USA) for 10 minutes at 98°C and 3 hours at 64°C, for DNA denaturation and sodium bisulfite 
conversion.  
After the incubation, samples were transferred to a Zymo-Spin IC™ column with 600 
µL of M-binding buffer and centrifuged for 30 seconds at 10 000 rpm. Then 100 μL M-Wash 
buffer were added and another centrifugation was performed. Following, 200 μL of M-
Desulphonation buffer was added to column and then incubated for 20 minutes at room 
temperature. An additional centrifugation, two washing steps were performed. 
Finally, the column was placed in a 1.5 mL tube to collect DNA by elution with sterile 
distilled water, incubation for 5 minutes at room temperature and 30 seconds of 
centrifugation at 12 000 rpm. This step was repeated, wherein the volume eluted was 
dependent on the initial quantity of DNA.  
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APPENDIX IV – RNA Extraction: TRIzol® 
 The RNA extraction solution (Trizol) was added to the pellet of cells and mixed with 
a syringe. After 5 minutes of incubation at room temperature, 200 µL of chloroform was 
added, and then incubated again for 3 minutes at room temperature. Following, a 15 
minutes’ centrifugation at 10 600 rpm, at 4°C, was performed, and the supernatant was 
transferred to RNAase free tubes. To RNA precipitation, 500 µL of isopropanol were added 
followed by incubation at room temperature for 10 minutes. After that, the samples were 
centrifuged at 10 600 rpm for 10 minutes, at 4°C, and the supernatant was discarded. 
Lastly, 1 mL of 75% ethanol was added to wash the pellet followed by a 5 minutes’ 
centrifugation at 8 400 rpm, at 4°C, and the supernatant was posteriorly rejected. Pellets 
were air dried and resuspended in 30-200 µL of RNA Storage Solution. After 30 minutes on 
ice, the RNA was storage at -80°C.  
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APPENDIX V – cDNA Synthesis: RevertAid Reverse Transcription Kit  
 The amount of RNA to synthetize 1000 nanograms was calculated for each sample, 
according to RNA concentration obtained, and sterile distillated water was added in order 
to achieve a final volume of 11 µL within PCR tubes. Additionally, 1 µL of Random Hexamer 
primer was added to the mixture and all the tubes were incubated at 65°C for 5 minutes in 
MyCycler™ Thermal Cycler System.  
 A mix containing 5x reaction buffer, ribolock RNase inhibitor (20 U/µL), 10 mM 
dNTPs Mix, and ReverAid RT (200 U/µL) was prepared with a total volume of 8 µL per well, 
and then added to the samples’ tubes. Lastly, tubes were centrifuged at 1 000 rpm for 1 
minute and submitted to one PCR cycle including 5 minutes at 25°C, 60 minutes at 42°C 
and 5 minutes at 70°C in MyCycler™ Thermal Cycler System. All the samples were storage 
at -20°C.     
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APPENDIX VI – Illustrations of drug-induced morphometric alterations  
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APPENDIX VII – Illustrations of drug-induced DNA damage 
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